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ABSTRACT OF THE DISSERTATION 
Batf regulates previously unknown AP-1 target genes to control TH17 differentiation 
by 
Barbara Ursula Schraml 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Immunology) 
Washington University in Saint Louis, 2009 
Professor Kenneth M. Murphy, Chairperson 
 
Activator protein 1 (AP-1) transcription factors are dimers of Jun, Fos, 
musculoaponeurotic fibrosarcoma (MAF) and activating transcription factor (ATF) 
family proteins that are characterized by a basic region and a leucine zipper domain.  
While many AP-1 proteins also contain defined transcriptional activation domains 
(TADs), some consist only of a basic region and leucine zipper and are thought to 
function as inhibitors of AP-1 activity.  We found that the AP-1 protein Batf, which lacks 
a TAD, is highly expressed in T helper cells compared to various other immune cells and 
tissues. IL-17-producing T helper (TH17) cells are a CD4+ T cell subset that coordinates 
inflammatory responses in host defense but are pathogenic in autoimmunity. To study the 
role of Batf in T cells, we generated Batf deficient mice by gene targeting. Batf -/- mice 
show a highly selective defect in TH17 differentiation. As a result, Batf -/- mice are 
completely resistant to experimental autoimmune encephalomyelitis. Using gene 
expression analysis, we found that Batf -/- T cells fail to induce known TH17-specific 
transcription factors, such as RORγt, and the cytokine IL-21, required for TH17 
differentiation.  Neither addition of IL-21 nor overexpression of RORγt fully restores IL-
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17 production in Batf -/- T cells, suggesting that Batf may be required directly for IL-17 
transcription. We found that the Il17 promoter is Batf-responsive, and upon TH17 
differentiation, Batf binds to several conserved intergenic elements in the Il17a/f locus as 
well as to regions in the Il17, Il21 and Il22 promoters. Using bio-computational methods 
we determined that the Batf-binding element in the Il17, Il21 and Il22 promoters differs 
from canonical symmetric AP-1 elements. Using EMSA analysis we found that Batf 
forms heterodimers preferentially with JunB during TH17 differentiation. These results 
demonstrate that the AP-1 factor Batf regulates previously unknown AP-1 target genes to 
control TH17 differentiation and TH17-mediated autoimmune disease.  
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CHAPTER 1 
Introduction 
 
The main function of the immune system is to recognize and eliminate pathogens. 
This defense against infectious microorganisms is mediated by coordinate responses of 
innate and adaptive immune cells. The innate immune system is a rapid first line of 
defense against pathogens. Innate immune cells sense pathogens via germline encoded 
receptors that recognize pathogen associated molecular patterns present on microbial 
organisms but not mammalian cells. Recognition of pathogens leads to immediate 
activation of innate immune cells and release of antimicrobial factors. In contrast, the 
adaptive immune system is composed of lymphocytes that can recognize a wide spectrum 
of pathogens and non-microbial derived molecules via highly specific antigen receptors. 
The adaptive immune response takes days rather than hours to develop and is instructed 
by the innate immune system to carry out pathogen specific effector functions of the 
appropriate effector class. Suitable adaptive immune responses ultimately result in the 
clearance of pathogens and the development of immunological memory, allowing for 
rapid recall responses the second time a pathogen is encountered.  
The ability of the immune systems to self-regulate after pathogens clearance and 
to regulate responsiveness to self antigens is of equal importance as mounting a strong 
immune response because uncontrolled immune responses contribute to autoimmune 
diseases, allergy and cancer development. The main driving force in regulating the 
expression of genes that promote immune cell development, differentiation, activation 
and regulation are transcription factors. A better understanding of the transcriptional 
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networks governing immune cell differentiation will contribute the knowledge necessary 
to develop novel therapeutic approaches to treat immunological diseases. 
 
Lymphocytes and the adaptive immune response 
The adaptive immune system can be divided into humoral and cell mediated 
immune responses. Humoral immune responses are mediated by B lymphocytes and refer 
to antibody production.  B lymphocytes produce and secrete antigen-specific antibodies 
that target pathogens for elimination by phagocytic cells or neutralize pathogens to 
prevent cell entry (Murphy et al., 2008). The nature of the humoral immune response is 
determined by the specific B cell subsets involved as well as the composition of the 
antigen. B cell responses include a variety of strictly controlled processes involved in the 
generation of antibody producing plasma cells, which secrete antigen specific antibodies 
with high affinity and distinct effector function, as well as the generation of memory B 
cells, armed for rapid release of antibodies upon reencountering antigen (Murphy et al., 
2008). 
Cell-mediated immune responses involve the activation of antigen specific CD4+ 
and CD8+ T lymphocytes and subsequential differentiation into functionally distinct 
effector T cells (Murphy et al., 2008). Activation of T cells involves the presentation of 
pathogen-derived peptides in the context of MHC molecules on the surface of antigen 
presenting cells (APC), since T cell receptors cannot recognize antigen in its native form. 
Upon activation, CD8+ T cells differentiate into cytotoxic T cells, which kill target cells 
that display pathogen-derived peptides from cytosolic pathogens, such as viruses, on their 
surface via MHCI. Activated CD4+ T cells differentiate into multiple subsets effector T 
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cells that orchestrate the adaptive immune response through the secretion of cytokines 
and other mechanisms. There are at least three classes of T helper (TH) cells known to 
date distinguished by their signature cytokines; TH1, TH2 and the recently identified TH17 
(Harrington et al., 2005) cells. In addition to differentiating into T helper subsets, naïve 
CD4+ T cells can develop into regulatory T cells (Treg) that are characterized by their 
ability to suppress T cell responses. At least one class of Treg cells develops in the thymus 
(natural Treg), but other classes of Treg cells develop in the periphery (adaptive Treg) 
(Weaver et al., 2006).  
 
T helper cell subsets in host defense 
T helper cells orchestrate immune responses through the secretion of their 
signature cytokines: TH1 cells are characterized by the production of IFN-γ and LTα, TH2 
cells secrete IL-4, IL-5 and IL-13 and TH17 cells secrete IL-17A (also called IL-17), IL-
17F and IL-22 (Weaver et al., 2006; Ouyang et al., 2008b). TH1 cells are the main players 
in cellular immunity against intracellular bacteria, viruses and tumors, while TH2 cells 
direct the humoral immune response to extracellular pathogens, such as helminthes. TH17 
cells mediate acute inflammatory responses and promote resistance to extracellular 
bacteria and fungi, particularly at mucosal surfaces. In addition to their importance in 
primary immune responses T helper cells produce large amounts of IL-2, which is 
required for the expansion of CD8+ memory T cells during secondary infections (Murphy 
and Reiner, 2002; Weaver et al., 2006). Uncontrolled helper T cell responses can lead to 
the development of atopic diseases such as asthma (TH2 mediated) or the development of 
autoimmune diseases (TH1 and TH17 mediated). Treg cells suppress immune responses 
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and prevent autoimmunity at least in part through the production of inhibitory cytokines 
such as IL-10 and TGF-β, as well as by inducing cytokine-deprivation-mediated 
apoptosis through the consumption of IL-2 (Vignali et al., 2008).  
In summary, T helper cells balance the immune response during infections and 
appropriate T helper cell responses determine the outcome of infectious and 
inflammatory responses. 
 
TH17 cells and autoimmunity 
Uncontrolled activation of T cells and uncontrolled production of effector T cell 
cytokines in response to self-antigens can lead to T cell mediated autoimmune diseases. 
Until recently, TH1 cells were thought to be the major pathogenic T cell subset in these 
diseases, based on observations that blocking the TH1 promoting cytokine IL-12 led to 
amelioration or cure of various autoimmune diseases. For instance, mice deficient for the 
p40 subunit of IL-12 or treated with neutralizing antibodies to IL-12 were protected from 
experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis 
(McGeachy and Cua, 2007). In apparent contradiction with these results targeting IFN-γ 
did not affect EAE development but in fact, IFN-γ deficient mice developed more severe 
disease indicating a protective role of IFN-γ in EAE (Willenborg et al., 1996).  Since IL-
12 is a heterodimer of a unique p35 subunit and a p40 subunit shared with IL-23 (Hunter, 
2005), studies targeting the IL-12 specific subunit provided conclusive evidence that TH1 
cells were negligible for the development of EAE (Gran et al., 2002). Instead, targeting 
IL-23 (p19 subunit) protected against EAE and lead to the identification of IL-23 as a 
crucial factor in EAE pathology through its role in maintaining the TH17 lineage 
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(Langrish et al., 2005). Additionally, mice deficient in transcription factors (Ivanov et al., 
2006; Brustle et al., 2007) and cytokines (Korn et al., 2007) required for TH17 
differentiation are protected from disease or develop less severe disease than wild type 
mice, providing additional evidence for the importance of TH17 cells in EAE pathology. 
However, even though the importance of TH17 cells in disease pathology is recognized, 
the major TH17 effector cytokines IL-17A, IL-17F and IL-22 contribute minimally to the 
disease (Kreymborg et al., 2007; Haak et al., 2009), indicating the existence of other 
effector pathways contributing to disease.  
TH17 cells and associated effector cytokines have been implicated in several other 
autoinflammatory disorders or models of autoinflammatory disorders, previously thought 
to be mainly TH1-mediated, including arthritis, inflammatory bowel disease, uveitis and 
psoriasis (McGeachy and Cua, 2007). In psoriasis patients IL-23 expression is readily 
detected in psoriatic lesions and decreased after commonly used treatments (Torti and 
Feldman, 2007). In murine models, IL-22 deficiency or neutralization of IL-22 protect 
against dermal inflammation (Zheng et al., 2007; Ma et al., 2008), while injection of mice 
with IL-23 promotes skin inflammation (Kopp et al., 2003). In several models of 
inflammatory bowel disease neutralization of IL-17, IL-6 or IL-23 and loss of IL-21 or 
IL-23 lead to disease amelioration (Yen et al., 2006; Fina et al., 2008; Elson et al., 2007). 
Thus, deciphering the molecular mechanisms underlying the differentiation of the 
inflammatory TH17 cell lineage will increase the understanding of inflammatory 
responses to foreign and self-antigens. This fundamental knowledge will provide the 
basis for the development of novel therapeutic approaches to treat autoinflammatory 
disorders. 
5
 Transcriptional regulation of TH1 and TH2 development 
The development of TH1 and TH2 effector cells is initially linked to instructive 
cytokine signals that induce the expression of cell specific transcription factors. 
Engagement of the T cell receptor on naïve T cells in conjunction with IFN-γ leads to the 
activation of signal transducer and activator of transcription (STAT) 1. STAT1 induces 
the expression of the TH1 specific T box family transcription factor T-bet. T-bet induces 
remodeling of the IFN-γ locus and likely stabilizes its own expression either through an 
intrinsic autocatalytic loop or an autocrine cytokine feedback loop involving IFN-γ 
signaling. T-bet also induces the transcription of the IL-12 receptor β2 subunit resulting 
in surface expression of a functional IL-12 receptor. IL-12 via STAT4 contributes to IFN-
γ transcription and induces the expression of IL-18 receptor. Once TH cells are committed 
to their fate they readily produce signature cytokines upon TCR stimulation without the 
need for exogenous cytokines signals. In TH1 cells, the responsiveness to IL-18 
potentiates an alternative, TCR independent pathway to induce cytokine expression, in 
response to IL-12 and IL-18 (Weaver et al., 2006; Murphy and Reiner, 2002). 
IL-4 promotes TH2 development through activation of STAT6 evident by the fact 
that STAT6 deficient T cells exhibit a severe reduction in TH2 differentiation.  STAT6 
induces low expression of the TH2 specific transcription factor Gata3, which stabilizes its 
own expression in a cell intrinsic feedback loop and regulates multiple TH2 associated 
cytokines by inducing epigenetic changes in the TH2 cytokine cluster (IL-4, IL-5 and IL-
13) (Ho et al., 2009). Gata3 is capable of inducing TH2 development in a STAT6 
independent manner at least in part by inducing the expression of other TH2-associated 
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transcription factors such as the AP-1 family member c-Maf, which directly regulates IL-
4 transcription in conjunction with  Gata3 (Ho et al., 1998; Murphy and Reiner, 2002). 
 TH1 and TH2 differentiation is stringently counter-regulated to ensure exclusive 
commitment to either lineage and once naïve T cells commit to the TH1 of TH2 lineage, 
they exhibit stable phenotypes, exclusively expressing their signature cytokines. Early 
TH2 signaling induces a rapid feedback loop ensuring stable expression of Gata3, thus 
promoting TH2 differentiation. This stable Gata3 expression additionally blocks TH1 
differentiation, since Gata3 inhibits expression of IFN-γ. Similarly, in TH1 cells T-bet 
inhibits the expression of TH2-associated factors and cytokines (Weaver et al., 2006; 
Murphy and Reiner, 2002).  
 
Transcriptional regulation of TH17 differentiation 
TH17 cells differentiate in response to the cytokines IL-6 and TGF-β (Bettelli et 
al., 2006; Korn et al., 2007; Nurieva et al., 2007; Wei et al., 2007; Zhou et al., 2007; 
Manel et al., 2008), while TGF-β signaling alone, in the absence of proinflammatory 
cytokines such as IL-6, induces the differentiation of Treg cells in an IL-2 dependent 
manner (Davidson et al., 2007). TH17 and Treg cells develop via reciprocal pathways, in 
which IL-6 inhibits TGF-β-mediated induction of the Treg specific transcription factor 
Foxp3 (Bettelli et al., 2006).  TH17 and Treg cell development were initially thought to be 
mutually exclusive but recent data suggest the existence of a bi-potential precursor, 
primed towards one or the other lineage depending on the strength of TGF-β signaling 
(Zhou et al., 2008). This shared requirement for TGF-β in the development of the 
inflammatory TH17 and the suppressive Treg lineages is intriguing as it implies a close 
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relationship of two cells with apparent opposite effector functions thus highlighting the 
necessity for balance in the adaptive immune response to pathogens.  
In addition to TGF-β and IL-6, TH17 differentiation requires IL-21, an early target 
of IL-6 signaling in T cells, which regulates TH17 differentiation via an autocrine 
feedback loop (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007; Wei et al., 
2007).  Additionally, IL-23 is required for the maintenance of TH17 cells (Langrish et al., 
2005; Veldhoen et al., 2006a). While IL-6, IL-21 and IL-23 are required for TH17 
differentiation and maintenance, proinflammatory cytokines such as IL-1β and TNF-α 
are not required but can further promote TH17 differentiation through unknown 
mechanisms (Veldhoen et al., 2006a).  
Similar to TH1 and TH2 cell differentiation, the differentiation of TH17 cells is 
counterregulated by effector cytokines from other TH subsets, such as IFN-γ, IL-4 and IL-
13. Additionally, the cytokines IL-2, IL-10 and IL-27, have been described to inhibit 
TH17 differentiation (Harrington et al., 2005; Park et al., 2005; Laurence et al., 2007; Gu 
et al., 2008; Newcomb et al., 2009; Awasthi et al., 2007; Diveu et al., 2009; Fitzgerald et 
al., 2007). In contrast to TH1 and TH2 cells, which exhibit stable cytokine secretion 
profiles once they are committed to their lineage, IL-17 double producing cells that also 
secrete IFN-γ are readily detected in vitro and in vivo. As a result TH1 and TH17 cells 
were thought to develop from a common precursor; however, lineage tracing experiments 
demonstrated that TH17 cells develop as a lineage distinct from TH1 cells (Veldhoen et 
al., 2006b). Nevertheless, recent data demonstrated that TH17 cells exhibit developmental 
plasticity and unstable cytokine expression and that the maintenance of a stable TH17 
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phenotype is strongly dependent on continuous IL-23 signaling (Shi et al., 2008; Lee et 
al., 2009). 
IL-6, IL-21 and IL-23 each activate STAT3 (Ghilardi and Ouyang, 2007), which 
is required for TH17 differentiation and potentially directly induces IL-17 production, 
since it binds directly to the Il17 promoter (Laurence et al., 2007; Yang et al., 2007; 
Mathur et al., 2007). Combined IL-6 and TGF-β signals induce the expression of the 
retinoid acid related nuclear orphan receptor (ROR) RORγt (Ivanov et al., 2006), a TH17 
specific transcription factor.  RORγt is sufficient to induce IL-17 production in wild type 
T cells and co-expressed with IL-17 in lamina propria T cells, which constitutively 
express IL-17. Since RORγt deficiency blocks TH17 differentiation in vitro (Ivanov et al., 
2006) RORγt is considered the main regulator of TH17 cells, similar to T-bet and Gata3 in 
TH1 and TH2 cells respectively. However, RORγt deficient mice are only partially 
resistant to EAE and residual IL-17 production can be observed in RORγt deficient T 
cells in vivo after EAE induction (Ivanov et al., 2006). This residual IL-17 production in 
RORγt deficient T cells has been attributed to functional redundancy between RORγt and 
RORα, another ROR family member expressed in TH17 cells (Yang et al., 2008). Yet, 
RORα is dispensable for TH17 differentiation since T cells deficient in RORα show only 
a mild reduction in IL-17 production (Yang et al., 2008). More strikingly, Irf4-/- T cells 
exhibit an absolute block in TH17 development and are completely resistant to EAE 
(Brustle et al., 2007). While Irf4-/- T cells exhibit decreased expression of RORγt, 
overexpression of RORγt in Irf4-/- T cells only partially restores IL-17 production 
(Brustle et al., 2007). Collectively, these data indicate that RORγt is unlikely the sole 
regulator of TH17 differentiation.  
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Consistently, additional factors have been identified to contribute to TH17 
differentiation. RUNX1 overexpression increases IL-17 production in wild type T cells 
and RUNX1 and RORγt synergize in Il17 reporter assays (Zhang et al., 2008a). 
Additionally, the aryl hydrocarbon receptor (AHR) is a TH17 specific ligand-dependent 
transcription factor that binds synthetic ligands, such as aromatic hydrocarbons, and 
naturally occurring ligands, such as tryptophan metabolites (Veldhoen et al., 2008). AHR 
deficient T cells lack IL-22 production but exhibit relatively normal IL-17 production, 
indicating that AHR is responsible for the transcriptional regulation of Il22, but not Il17 
(Veldhoen et al., 2008; Quintana et al., 2008). Nevertheless, AHR ligands are necessary 
for optimal differentiation of TH17 cells (Veldhoen et al., 2009). To summarize, multiple 
transcription factors have been shown to control TH17 differentiation, but their 
transcriptional hierarchy and cooperativity are incompletely understood.  
  
The AP-1 family of transcription factors 
AP-1 proteins are members of the Jun (Jun, JunB, JunD), Fos (Fos, FosB Fra1, 
Fra2), musculoaponeurotic fibrosarcoma (MAF) and activating transcription factor (ATF) 
families. They are basic leucine zipper (bZIP) proteins that are characterized by a basic 
region for DNA binding and leucine zipper that mediates dimerization (Vinson et al., 
2006). Most AP-1 proteins contain defined transcriptional activation domains (TADs), 
but some consist only of a basic region and leucine zipper and are thought to function as 
inhibitors of AP-1 activity (Blank, 2008; Williams et al., 2001; Echlin et al., 2000; 
Iacobelli et al., 2000; Dorsey et al., 1995; Thornton et al., 2006). AP-1 family members 
require dimerization to form functional transcription factor complexes. While Fos family 
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members can only heterodimerize with Jun proteins, Jun proteins can homo- or 
heterodimerize to form active transcription factors. Additionally, AP-1 proteins often 
cooperate with other transcription factors to induce target genes.  AP-1 complexes 
generally bind to dyad symmetric DNA sequences, such as TGANTCA (TRE element) 
and TGANNTCA (CRE element) and AP-1 proteins are also regulated by upstream 
kinases connecting them to various signal transduction pathways (Ryseck and Bravo, 
1991; Eferl and Wagner, 2003; Wagner and Eferl, 2005).  
 The functions of individual family members have been elucidated using 
genetically modified mice. These studies revealed essential functions of AP-1 in various 
processes, including embryonic development, behavior, bone formation as well as 
immune cell development and function (Eferl and Wagner, 2003).  
 
AP-1 dependent regulation of T cell differentiation and cytokine production 
AP-1 family proteins regulate multiple stages of T cell development, 
differentiation and cytokine production (Hess et al., 2004). Many cytokine promoters are 
regulated by AP-1 often in cooperation with other transcription factors (Macian et al., 
2001); for example the extensively studied IL-2 promoter is regulated by AP-1 in 
conjunction with NFAT (Garrity et al., 1994; Jain et al., 1992). AP-1 transcriptional 
activity has been analyzed in T cells using AP-1-luciferase transgenic mice. These studies 
revealed higher AP-1 activity in TH2 cells compared to TH1 cells (Rincon et al., 1997), 
despite expression of AP-1 proteins in both effector subsets. JunB is preferentially 
expressed in TH2 cells compared to TH1 cells, whereas the expression of JunD and c-Jun 
is similar between the two subsets (Rincon et al., 1997). Overexpression of JunB leads to 
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ectopic expression of TH2 cytokines in T cells cultured under TH1 conditions (Li et al., 
1999), whereas JunB deficient T cells exhibit inefficient skewing towards a TH2 
phenotype (Hartenstein et al., 2002). In contrast, overexpression of JunD suppresses TH2 
cytokine expression and JunD deficiency leads to increased TH1 and TH2 cytokine 
production (Meixner et al., 2004). Therefore, JunB promotes TH2 differentiation, while 
JunD acts as a negative regulator of cytokine production in T cells. In addition to Jun 
family members several MAF family members control T cell function and cytokine 
production. c-Maf regulates IL-4 production in TH2 cells (Ho et al., 1996) and transgenic 
overexpression of MafK, a potential AP-1 transcriptional inhibitor, suppresses T cell 
proliferation (Yoh et al., 2001). In summary, AP-1 family members regulate T helper cell 
development, maintenance and cytokine production, thus controlling the balance of T cell 
differentiation during specific responses to pathogens. 
 
 Batf as a regulator of AP-1 transcriptional activity 
Batf is a member of the AP-1 family of proteins but unlike most other AP-1 
proteins, Batf is composed only of a basic region and leucine zipper and lacks obvious 
transactivation domains (TADs) (Dorsey et al., 1995). Batf forms heterodimers with Jun 
but not Fos proteins (Echlin et al., 2000; Dorsey et al., 1995; Senga et al., 2002; 
Hasegawa et al., 1996). In reporter assays Batf can inhibit AP-1 dependent luciferase 
activity in vitro and in vivo as well as cellular transformation by Fos (Thornton et al., 
2006; Williams et al., 2001; Echlin et al., 2000). Thus, Batf has been suggested to 
function as an endogenous repressor of AP-1 activity, by forming transcriptionally inert 
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complexes with Jun proteins that exhibit identical DNA binding specificity as the Jun/Fos 
complexes (Echlin et al., 2000; Thornton et al., 2006; Williams et al., 2001).  
 Batf was initially cloned from a B cell line (Dorsey et al., 1995), but is also 
expressed in T cells and induced by activation through the T cell receptor (Williams et 
al., 2001). Subsequent studies analyzed Batf function by overexpression as a transgene 
under the proximal lck promoter which confers expression at early stages of T cell 
development. In this context, Batf overexpression severely reduced NKT cell 
development (Williams et al., 2003; Zullo et al., 2007) and thymocyte proliferation. It is 
not clear from these studies, whether the reduced thymocyte proliferation in Batf 
transgenic mice is due to a T cell intrinsic defect or secondary to the absence of NKT cell 
derived cytokines, since total thymocytes were analyzed (Williams et al., 2003). 
Nevertheless, Batf is a potential inhibitor of AP-1 transcription expressed in T cells that 
affects T cell differentiation by overexpression.  
 
In the studies presented here, we identify a critical role for Batf in TH17 
differentiation and we found that Batf is expressed highly in T helper cells compared to 
various other immune cells and tissues. We generated Batf deficient mice by gene 
targeting. Batf -/- mice show a highly selective defect in TH17 differentiation and are 
resistant to experimental autoimmune encephalomyelitis. Using gene expression analysis, 
we found that Batf -/- T cells fail to induce known TH17-specific transcription factors, 
such as RORγt, and the cytokine IL-21, required for TH17 differentiation.  Neither 
addition of IL-21 nor overexpression of RORγt fully restores IL-17 production in Batf -/- 
T cells, suggesting that Batf may be required directly for IL-17 transcription. We found 
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that the Il17 promoter is Batf-responsive, and upon TH17 differentiation, Batf binds to 
several conserved intergenic elements in the Il17a/f locus and to regions in the Il17, Il21 
and Il22 promoters. Using bio-computational methods we determined that the Batf-
binding element in the Il17, Il21 and Il22 promoters differs from canonical symmetric 
AP-1 elements. Using EMSA analysis we found that Batf forms heterodimers 
preferentially with JunB during TH17 differentiation. These results demonstrate that Batf 
regulates previously unknown AP-1 target genes to control TH17 differentiation and 
TH17-mediated autoimmune disease.  
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CHAPTER 2 
Experimental Methods 
 
Generation of mice.  Murine Batf exons 1–2 were deleted by homologous recombination 
via a targeting vector constructed in pLNTK(Gorman et al., 1996) using a 1 kb genomic 
fragment (left arm) upstream of the Batf exon 1 and a 3.6 kb genomic fragment (right 
arm) downstream of exon 2. The left arm was generated by PCR from genomic DNA 
with the use of the following oligonucleotides: left arm forward (5’-
ATTACTCGAGTGAAACAAACAGGCAGTCGCAGTG) and left arm reverse (5’-
ATTACTCGAGCCTACTACCTTTCAGGGCTACTGC).  The right arm was generated 
by PCR with the use of the following oligonucleotides: right arm forward (5’-
ATTAGTCGACGCATTCTTCATGGTCCTTAGCCTTGG) and right arm reverse (5’-
ATTAGTCGACCAGAGAATGAGAAATGTTGGAGG).  EDJ22 embryonic stem cells 
were transfected with linearized targeting vector and targeted clones were identified by 
Southern blot analysis using probes A and B located 5’ to the left arm and 3’ to the right 
arm respectively.  Probe A was generated using the oligonucleotides 5’-
CAACTGGGTCTGAGTCAAGAGGT and 5’-CGTAGCCGCTGATTGTTTTAGAAC 
to generate a 531bp product.  Probe B was generated using the oligonucleotides 5’-
ACAGCTTGAACTTCAGAGCCCTCC and 5’-
CACATTTAAGTCACAATAACACTGC to generate a 772bp product.  The neomycin 
resistance cassette was deleted from successfully targeted clones by in vitro treatment 
with Adeno-Cre virus (gift from Dr. Barry Sleckman, Washington University, St. Louis, 
MO) and targeted clones with successful neo deletion were identified by Southern blot 
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using probes A and B (Supplementary Fig.1b and c). Blastocyst injections were 
performed with two distinct recombinant clones each of which generated germline 
transmission of the targeted Batf allele.  Male chimeras were crossed with 129SvEv 
females to establish Batf mutants on the pure 129SvEv genetic background.  All 
experiments were performed with mice harboring the neo-deleted mutant allele.  
Homozygous mice were obtained by intercrossing heterozygous siblings and littermates 
were used as controls in most experiments.  For some experiments 129SvEv wild type 
mice purchased from Taconic served as controls.  For experiments with DO11.10 
transgenic Batf -/- mice, mice were crossed to BALB/c mice for at least 5 generations and 
littermate controls were used as control. 
For the generation of transgenic mice, Batf cDNA was cloned from CD4+ T cell 
mRNA using primers 5’-GGAAGATTAGAACCATGCCTC and 5’-
AGAAGGTCAGGGCTGGAAG and subcloned into the GFP-RV retrovirus (Ranganath 
et al., 1998).  An N-terminal FLAG tag was introduced by Quick Change Mutagenesis kit 
(Stratagene) using the primers 5’-
GGACTACAAAGACGATGACGACAAGCCTCACAGCTCCGACAGCA and 5’-
CTTGTCGTCATCGTCTTTGTAGTCCATGGTTCTAATCTTCCAGATC.  The 
underlined sequence indicates nucleotides used to introduce the FLAG-tag.  The FLAG-
tagged Batf was cloned into the CD2 microinjection cassette(Zhumabekov et al., 1995) 
via blunt end strategy into Sma1 digested CD2 microinjection cassette.  Transgene 
expression in CD4+ T cells was tested by anti-FLAG western blot.  CD2-N-FLAG-Batf 
transgenic mice were crossed to C57BL/6 and BALB/c mice for at least 5 generations.  
Transgene-negative littermates were used as control mice.  Mice were bred and 
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maintained at the animal facilities at Washington University in St. Louis.  All animal 
experiments were approved by the Animal Studies Committee at Washington University. 
 
Visualization of lymph nodes. To visualize superficial inguinal lymph nodes mice were 
injected with 50μl of 1% Evans Blue dye solution into each hind foot pad. After 1.5 
hours mice were sacrificed and lymph nodes were visualized using a dissecting 
microscope(Sun et al., 2000). 
 
Western Blot analysis. To test for residual Batf protein expression, total splenocytes 
from Batf +/+ and Batf -/- 129SvEv mice were stimulated with anti-CD3 for 3 days under 
TH17 conditions. Cells were then lysed in RIPA buffer, electrophoresed on 15% 
polyacrylamide gels, transferred to nitrocellulose and analyzed by Western Blot with 
rabbit anti-murine Batf polyclonal serum and HRP-conjugated anti-rabbit Ig antibody 
(Jackson ImmunoResearch). Affinity purified rabbit anti-murine Batf polyclonal serum 
(Brookwood Biomedical; Birmingham, AL) was generated by immunization with full 
length recombinant Batf protein. Equal protein loading was assessed by subsequent 
immunoblotting with antibody to β-actin (Santa Cruz Biotechnology) and HRP 
conjugated anti-mouse antibody (Jackson ImmunoResearch).  
For analysis of Batf protein expression in naïve CD4+ T cells, magnetically 
purified CD4+ T cells from Batf +/+ and Batf -/- 129SvEv mice were isolated. Equal cell 
numbers were lysed in RIPA buffer and subjected to Western Blot analysis as described 
above.  
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For analysis of Batf expression in TH2 cells, magnetically purified CD4+ T cells 
from Batf +/+ and Batf -/- mice were activated with anti-CD3/CD28 in the presence of IL-4, 
anti-IL-12 (Tosh), and anti-IFNγ (H22). On day 4 cells were left unstimulated or 
stimulated with PMA/ionomycin for 4 hrs.  Cells were collected by centrifugation, 
washed with PBS, and resuspended (100e6 cells/ml) in Affymetrix Chip lysis buffer 
(10mM Tris pH 7.5, 10mM NaCl, 3mM MgCl2, 0.5% IGEPAL, with protease inhibitors 
(PMSF, aprotinin, leupeptin)).  After 5 min at 4oC, nuclei were collected by 
centrifugation (800 rcf for 3 min 4oC) and lysed in RIPA (100e6 cell equivalents/ml) with 
protease inhibitors.  Nuclear lysates were centrifuged for 10 min 4oC 15000 rcf and 
diluted with an equal volume of 2x SDS-PAGE sample buffer containing 2-ME. Nuclear 
extracts from equal cell numbers were subjected to Western Blot analysis using affinity 
purified rabbit anti-murine Batf polyclonal serum. Equal protein loading was assessed by 
subsequent immunoblotting with antibody to Lamin B (Santa Cruz Biotechnology) and 
HRP conjugated anti-goat Ig (Jackson ImmunoResearch). 
 
Immunohistochemistry. To test for cellular localization of Batf, CD4+ T cells from 
CD2-N-FLAG-Batf transgenic mice were isolated by magnetic separation and either left 
untreated or stimulated with PMA/ionomycin for 4h. Cells were then allowed to settle on 
poly-L-lysine treated slides, fixed with 4% Formaldehyde, permeabilized with 0.25% 
TritonX100 and were stained with an anti-FLAG antibody (M2, Sigma Aldrich) 
according to the manufacturer’s recommendations. A goat anti-mouse AF-488 
(Invitrogen) antibody was to detect anti-FLAG staining. For analysis of cellular 
localization of Batf in TH2 cells, DO11.10 CD4+ T cells from CD2-N-FLAG-Batf 
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transgenic mice were isolated and differentiated with OVA and APC under TH2 
conditions for 7 days. On day 7 cells were either left untreated or stimulated with 
PMA/ionomycin for 4h. Cells were stained with anti-FLAG antibody as described above. 
Cells were also stained with anti-CD4APC antibody (BDBiosciences). Confocal images 
were obtained with the Olympus FV1000 microscope and software using a 60x oil 
objective. The pinhole was set to 110μm. The excitation/emission settings used for DAPI, 
Alexa 488 and Alexa 633 were 405/461nm, 488/520nm and 635/668nm respectively. 
 
Flow cytometry. All flow cytometric data was collected on a FACS Calibur or FACS 
Canto (both BD Biosciences) and analyzed using FloJo analysis software (Tree Star, 
Inc.). 
The following antibodies were purchased from BD Biosciences; anti-CD4-
Allophycoerythrin (APC), CD4-Phycoerythrin (PE)/Cy7 (RM4-5), anti-CD8-APC (53-
6.7), anti-CD44-APC (IM7), anti-CD62L-PE (Mel14), anti-CD3-APC (145-2C11), anti-
IgM-PE (II/41), anti-B220 Fluorescein isothiocyanate (FITC) (RA3-6B2), anti-IL-17-PE 
(TC11-18H10), anti-IFNγ- PE (XMG1.2), anti-IFNγ-APC, anti-IL-4-APC (11B11), anti-
IL-10-APC (JES5-16E3), anti-CD16/32 (2.4G2), anti-CD11c-PE (HL3), anti-CD11b-
PECy7 (M1/70)), anti-CD44-APC (1M7), anti-CD25-APC (3C7), anti-phospho Stat3-
AlexaFluor 647 (4/P-Stat3), Streptavidin-PeCy7, 7-AAD, AnnexinV-FITC and 
AnnexinV staining solution.  
The following antibodies and solutions were purchased from eBioscience; anti-
AA4.1 APC (AA4.1), anti-IgD PE (11-26c), IL-17A-FITC (eBio17B7), anti-Foxp3 (FJK-
16s) and Foxp3 staining buffers.  
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Anti-CD4-FITC and anti-CD8-FITC were purchased from Invitrogen. Anti-
Dec205-biotin (MG38) was purchased from Cedarlane. CD1d-PBS57-PE and CD1d-
unloaded-PE tetramers were obtained from the tetramer facility at the NIH. Anti-IL-22 
(RMF 222CK) was purchased from Antigenix.  
Intracellular Staining. For intracellular cytokine staining cells were stained with 
antibodies to surface markers followed by fixation with 2% formaldehyde for 15 minutes 
at room temperature. Cells were then washed once in 0.05% saponin and stained with 
anti-cytokine antibodies in 0.5% saponin as described previously(Berenson et al., 2004).  
Anti-phospho-STAT3 antibody was purchased from BD Pharmingen and cells were 
stained according to the manufacturer’s recommendations. Briefly, cells were stained for 
surface markers followed by fixation with 90% methanol at -20oC overnight. Cells were 
then washed and stained for phospho-STAT3 in PBS containing 3% FCS. For Foxp3 
staining, cells were stained using Foxp3 staining buffers (eBioscience) according to the 
manufacturer’s recommendations.  
 
Isolation of dendritic cells for flow cytometry. Spleens were isolated, cut into small 
pieces and digested with Collagenase B (Roche) and DNase I (Sigma) for 30 min at 37oC. 
Red blood cells were lysed by incubation with Red Blood Cell Lysis Buffer (Sigma) (1 
minute at room temperature). Single cell suspensions were prepared by passing digested 
spleens through 35μm nylon cell strainers (Fisher Scientific) and were stained with 
antibodies for analysis by Flow Cytometry.  
 
Isolation of naïve T cells. Splenic single cells suspensions were generated and red blood 
cells were lysed by incubation with Red Blood Cell Lysis Buffer (Sigma) (1 minute at 
room temperature). Splenocytes were then negatively depleted of B220+ and CD8+ cells 
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using magnetically labeled beads followed by depletion over LD columns (all Miltenyi 
Biotec).  The depleted fraction was then stained with antibodies to CD4, CD62L and 
CD25 (all BD Biosciences) and CD4+CD62L+CD25- cells were sorted on a MoFlo 
cytometer. Sort purity was generally >98%.   For some experiments, as indicated, CD4+ T 
cells were isolated from spleens by incubation with anti-CD4 magnetic beads and 
selection via LS columns (Miltenyi Biotec) according to the manufacturer’s 
recommendations. 
 
Cell culture. For T cell differentiation assays, sorted naïve CD4+ CD62L+CD25- T cells 
or magnetically purified CD4+ T cells were isolated as indicated. Cells were cultured at 
0.5x106 cells/well in 48 well plates containing plate-bound anti-CD3 (from ascites) and 
soluble anti-CD28 (37.5; BioXcell; 4μg/ml). Stimulation of cells without the addition of 
cytokines was defined as drift condition. Cultures were supplemented with anti-IL-4 
(11B11; hybridoma supernatant), IFNγ (Peprotech; 0.1ng/ml) and IL-12 ( Genetics 
Institute; 10U/ml) for TH1; anti-IFNγ (H22; BioXcell; 10μg/ml), anti-IL-12 (Tosh; 
BioXcell; 10μg/ml) and IL-4 (Peprotech; 10ng/ml) for TH2; anti-IL-4, anti-IL-12, anti-
IFNγ, IL-6 (Peprotech; 20ng/ml) and TGF-β (Peprotech; 0.5ng/ml) for TH17 
differentiation. In some experiments, cultures were supplemented with IL-21 (50ng/ml; 
all Peprotech), anti-IL-6 (MP5-20F3; eBioscience; 10μg/ml), anti-TGF-β (1D11, R&D 
Biosystems, 10μg/ml) or anti-IL-2 (JES6-1A12; BioXcell; 10μg/ml) as indicated. For 
drift, TH1 and TH2 conditions cells were restimulated on day 7 with anti-CD3 and anti-
CD28. Brefeldin A was added for the last 4 hours of stimulation. For TH17 conditions, 
cells were restimulated on day 3 or day 7 after activation as indicated with Phorbol 12-
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myristate 13-acetate (PMA) (50ng/ml; Sigma) and ionomycin (1μM; Sigma) for 4 hours 
in the presence of Brefeldin A (1μg/ml; Epicentre). Cells were then analyzed by 
intracellular cytokine staining and flow cytometry. 
In some experiments, as indicated, magnetically purified CD4+ T cells from 
DO11.10 transgenic mice were activated with OVA (3μM) and irradiated splenocytes in 
the presence of anti-IL-4, anti-IL-12, anti-IFNγ, IL-6 and TGF-β (1ng/ml) to induce TH17 
differentiation.   
To induce TH17 differentiation in total splenocytes, single cells suspensions from 
spleens were prepared and red blood cells were lysed. Total splenocytes were activated at 
4x106 cells/well in 12 well plates containing plate-bound anti-CD3, anti-IL-4 (hybridoma 
supernatant), anti-IL-12 (10μg/ml), anti-IFNγ (10μg/ml), IL-6 (20ng/ml) and TGF-β 
(1ng/ml).  Cells were restimulated with PMA and ionomycin for 4h in the presence of 
Brefeldin A before intracellular cytokine staining and analysis by flow cytometry. 
For STAT3-phosphorylation assays magnetically purified CD4+ or CD8+ T cells were 
stimulated with anti-CD3 and anti-CD28 in the presence of IL-6 or IL-21 (50ng/ml) 
followed by intracellular staining and analysis by flow cytometry.  
 
ELISA. The concentration of IL-21 in supernatants from CD4+ T cells activated for 3 
days under TH17 conditions was determined by ELISA (R&D Systems) according to the 
manufacturer’s recommendations.  
 
Isolation of Lamina Propria T cells. For isolation of lamina propria T cells, mice were 
sacrificed; small intestines removed, placed in cold DMEM media (10%FCS) and cleared 
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of Peyer’s patches and residual mesenteric fat tissue. Intestines were then opened 
longitudinally, cleared of contents and cut into 0.5cm pieces. The pieces were washed 
multiple times in cold media and twice in ice cold Citrate BSA (CB-BSA) buffer 
followed by two 15 minute incubations in CB-BSA with agitation. After each incubation 
cells were vortexed to remove epithelial cells. The remaining intestinal pieces were then 
washed twice with cold media before digestion in media containing 75U/ml Collagenase 
IV (Sigma) at 37oC for 1 hour. The solution was vortexed at 20 min intervals to detach 
lymphocytes. After one hour the solution was filtered through a 35μm strainer, the pieces 
were collected and digested a second time. Supernatants from both digestions were 
combined, washed once, suspended in the 70% fraction of a percoll gradient and overlaid 
with 37% and 30% percoll gradient fractions. Lymphocytes were collected at the 70-37% 
interface, washed once in PBS and stimulated with PMA/ionomycin in the presence of 
Brefeldin A for 3 hours before cells were stained for extracellular markers and 
intracellular cytokines.  
 
Induction of EAE and disease scoring. Age and sex matched mice (7-10 weeks old) 
were immunized subcutaneously with 100μg MOG35-55 peptide (Sigma) emulsified in 
CFA (IFA supplemented with 500μg Mycobacterium tuberculosis) on day 0. On days 1 
and 3, mice were injected with 300ng Pertussis Toxin (List Biological Laboratories) 
intraperitonally (i.p.). Clinical scores were given on a scale of 1-5 as follows: 0, no overt 
signs of disease; 1, limp tail or hind limb weakness, but not both; 2, limp tail and hind 
limb weakness; 3, partial hind limb paralysis; 4, complete hind limb paralysis; 5, 
moribund state or death by EAE. Mice with a score of 4 were given 300 μl saline solution 
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subcutaneously to prevent dehydration. Mice with a score of 5 were euthanized. Some 
mice died during the course of the experiment. Their score of 5 was included in the 
analysis for the remainder of the experiment. For T cell transfer experiments, CD4+ T 
cells were isolated from splenic single cell suspensions by magnetic separation with anti-
CD4 magnetic beads and positive selection via LS columns (Miltenyi Biotec). 1x107 
MACS purified CD4+ T cells were injected i.p. on day -4 followed by EAE induction on 
day 0 as described above.  
 
Isolation of CNS lymphocytes. Brain and spinal cords were removed from mice after 
perfusion with 30ml of saline solution. Single cell suspensions were prepared by 
dispersion through sterile 35μ nylon cell strainers (Fisher Scientific) and mixed at room 
temperature for 1hr in HBSS containing 0.1% collagenase, 0.1μg/ml TLCK (N-α-tosyl-
L-lysine chloromethylketone hydrochloride), and 10μg/ml DNaseI (all Sigma). The 
resulting suspension was pelleted, resuspended in the 70% fraction of a Percoll gradient 
and overlaid by additional 37% and 30% layers. The Percoll gradient separation was 
achieved by centrifugation for 20 min at 2000rpm and lymphocytes were collected at the 
70-37% interface.  Subsequently cells were activated with PMA and ionomycin for 3-4 
hours in the presence of Brefeldin A and intracellular cytokine staining was performed. 
  
Real time PCR. Naïve CD4+CD62L+CD25- T cells were isolated by cell sorting and 
activated with plate-bound anti-CD3 and soluble anti-CD28 antibodies under TH17 
conditions for 3 days, unless otherwise indicated. Total RNA was isolated from the 
indicated cells using Quiagen RNeasy Mini Kit and cDNA was synthesized using 
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SuperscriptIII reverse transcriptase (Invitrogen).  Real time PCR analysis was performed 
using ABI SYBR Green master mix according to the manufacturer’s instructions on an 
ABI7000 machine (Applied Biosystems) using the relative standard curve method. The 
PCR conditions were 2min at 50oC, 10 min at 95oC followed by 40 2-step cycles of 15s at 
95oC and 1min at 60oC. 
Primers for RORγt (RORγt forward 5’-CGCTGAGAGGGCTTCAC, RORγt 
reverse 5’-GCAGGAGTAGGCCACATTACA)(IVANOV ET AL., 2006), IL-21 (IL-21 
forward 5'-ATCCTGAACTTCTATCAGCTCCAC, RORα ( RORα forward 5’- 
TCTCCCTGCGCTCTCCGCAC-3’, RORα reverse 5’ TCCACAGATCTTGCATGGA-
3’)(YANG ET AL., 2008), IL-21 reverse 5′-
GCATTTAGCTATGTGCTTCTGTTTC)(Zhou et al., 2007), IL-22 (IL-22 forward-5’ 
CATGCAGGAGGTGGTACCTT, IL-22 reverse- 5’- 
CAGACGCAAGCATTTCTCAG)(Chung et al., 2006), IL-23R (IL-23R forward 5’- 
GCCAAGAAGACCATTCCCGA, IL-23R reverse 5’- 
TCAGTGCTACAATCTTCTTCAGAGGACA)(MANGAN ET AL., 2006), IRF-4 (IRF-
4 forward 5'-GCCCAACAAGCTAGAAAG, IRF-4 reverse: 5'-
TCTCTGAGGGTCTGGAAACT) (Negishi et al., 2005) and HPRT as normalization 
control (HPRT forward 5’-AGCCTAAGATGAGCGCC, HPRT reverse 5’-
TTACTAGGCAGATGGCCACA) were used to evaluate relative gene expression.  
For analysis of acute phase response proteins, mice were injected intraperitonally 
with either 0.9% saline solution or IL-6 (0.3μg per mouse) in 0.9% saline solution. Four 
hours later, total liver RNA was isolated using Trizol reagent (Invitrogen) according to 
the manufacturer’s recommendations. cDNA was synthesized and real time PCR 
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performed as described above. Primers used for serum amyloid protein P (SAP forward: 
5’-TTTCAGAAGCCTTTTGTCAGA and SAP reverse: 5’-
AAGGTCACTGTAGGTTCGGA) (Korbelik et al., 2008), c-reactive protein (CRP 
forward: 5’- TTCTGGATTGATGGGAAAAGC and  
CRP reverse: 5’- AAACATTGGGGCTGAGTGTC)(Korbelik et al., 2008), Serum 
amyloid protein A (SAA forward 5'-TCTCTGGGGCAACATAGTATACCTCTCAT and  
SAA reverse 5'-TTTATTACCCTCTCCTCCTCAAGCAGTTAC) (Dierssen et al., 2008), 
fibrinogen β (fibß forward: 5'-ATTAGCCAGCTTACCAGGATGGGACCCAC-3',  
Fibß reverse: 5'-CAGTAGTAT CTGCCGTTTGGATTGGCTGC-3')(Chauvet et al., 
2005), alpha-1-acid glycoprotein (AGP forward: TCT CTG AAC TCC GAG GGC TG  
AGP reverse: GAGACAGAATCAAAGTGCACAGGA)(Theilgaard-Monch et al., 2005) 
and HPRT as normalization control (HPRT forward 5’-AGCCTAAGATGAGCGCC, 
HPRT reverse 5’-TTACTAGGCAGATGGCCACA) were used to evaluate relative gene 
expression. 
 
Gene expression profiling.  Naïve CD4+ CD62L+ CD25- T cells and CD4+ CD62L+ 
CD25+ regulatory T cells were isolated from C57BL/6 mice. Naïve CD4+ CD62L+ CD25- 
T cells were differentiated under TH1 and TH2 conditions for 7 days.  After restimulation 
with anti-CD3 and anti-CD28 for 24h, TH1 and TH2 cells were sorted for IFNγ and IL-4 
production respectively using cytokine secretion assays (Miltenyi Biotec) according to 
the Manufacturer’s recommendations. For gene expression profiling of TH17 cells, naïve 
CD4+ CD62L+ CD25- T cells were activated for 3 days with anti-CD3 and anti-CD28 in 
the presence of anti-IL-4, anti-IL-12, anti-IFNγ, anti-IL-2, IL-6 and TGF-β (0.5ng/ml). 
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For gene expression analysis in Batf -/- T cells, naive CD4+ CD62L+ CD25- T cells from 
Batf +/+ and Batf -/- mice were activated for 3 days with anti-CD3 and anti-CD28 in the 
presence of either anti-IL-4, anti-IL-12, anti-IFNγ, IL-6 and TGF-β (0.5ng/ml); anti-IL-4, 
anti-IL-12, anti-IFNγ, IL-6 and anti-TGF-β; anti-IL-4, anti-IL-12, anti-IFNγ, anti-IL-6 
and TGF-β or anti-IL-4, anti-IL-12, anti-IFNγ, anti-IL-6 and anti-TGF-β. IL-2 was 
neutralized in all conditions.  Total RNA was isolated from cells using Quiagen RNeasy 
Mini Kit. Biotinylated antisense cRNA was generated using two cycle target preparation 
kit (Affymetrix). After fragmentation, cRNA was hybridized to Affymetrix GeneChip 
Mouse Genome 430 2.0 Arrays. Data were normalized and expression values were 
modeled using DNA-Chip analyzer (dChip) software (www.dChip.org). 
 
Retroviral infection and analysis.  mRNA was isolated from 129SvEv total thymocytes 
using Quiagen RNAeasy Mini Kit and cDNA was amplified by SuperscriptIII 
(Invitrogen). Murine RORγt transcript was amplified using primers 5’-
CTCGAGGTGTGCTGTCCTGGGCTAC and 5’-
CTCGAGGGGAGACGGGTCAGAGGG. Underlined nucleotides indicate XhoI 
overhangs used to clone RORγt into XhoI digested GFP-RV retrovirus(Ranganath et al., 
1998) or XhoI digested hCD4-RV(Zhu et al., 2001).  
Batf cDNA was cloned from CD4+ T cell mRNA using primers 5’-
GGAAGATTAGAACCATGCCTC and 5’-AGAAGGTCAGGGCTGGAAG and 
subcloned into the GFP-RV retrovirus(Ranganath et al., 1998).  An N-terminal FLAG tag 
was introduced by Quick Change Mutagenesis kit (Stratagene) using the primers 5’-
GGACTACAAAGACGATGACGACAAGCCTCACAGCTCCGACAGCA and 5’-
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CTTGTCGTCATCGTCTTTGTAGTCCATGGTTCTAATCTTCCAGATC.  The 
underlined sequence indicates nucleotides used to introduce the FLAG-tag. 
The retrovirus based reporter hCD4-pA-GFP-RV(Zhu et al., 2001), in which a 
cytoplasmic truncated human CD4 (hCD4) marks viral infection and green fluorescence 
protein (GFP) is used to report promoter activity has been described previously and was 
modified as follows to generate hCD4-pA-GFP-RV-IL-17p. The 1021bp promoter region 
of murine IL-17a was generated by PCR from genomic 129SvEv DNA using primers 5’-
AGCTTGAACAGGAGCTATCGGTCC and 5’-
AAGCTTGAGGTGGATGAAGAGTAGTGC. Underlined nucleotides indicate 
overhangs containing HindIII restriction sites used to clone the resulting PCR product 
into hCD4-pA-GFP-RV.   
Retroviral vectors were packaged in Phoenix E cells as described previously 
(Ranganath et al., 1998). Magnetically purified CD4+ T cells were infected with viral 
supernatants on days 1 and 2 after activation with anti-CD3 and anti-CD28. 3 days after 
activation cells were restimulated with PMA/ionomycin in the presence of Brefeldin A 
and analyzed by intracellular cytokine staining and Flow Cytometry.  For the experiments 
in Figure 4, CD4+ T cells from Batf +/+ and Batf -/- mice were activated under TH17 
conditions and infected with the IL-17 reporter virus. Stably infected T cells were 
restimulated with PMA/ionomycin for 4h and examined for GFP expression on day 3 
after initial activation. 
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Statistical Analysis.  A Student’s unpaired two-tailed t-test was used to indicate 
statistically significant differences between indicated groups. Differences with a P value 
<0.05 were considered significant.   
 
Electrophoretic mobility shift assays.  Whole cell extracts were prepared from total 
splenocytes activated for 3 days with anti-CD3, TGF-β and IL-6 as described previously 
(Nakshatri and Currie, 1996). For EMSA analysis the AP-1 consensus probe(Echlin et al., 
2000) (top: AGCTTCGCTTGATGAGTC and bottom: GCCGACTGAGTAGTTCGC), 
RORE element in CNS2 of the IL-17 gene(Yang et al., 2008) (top: 
GAAAGTTTTCTGACCCACTTTAAATCA and bottom: 
CTTTAACTAAATTTCACCCAGTCTTTT) 
and -187 to -155 of the IL-17 promoter (top: 
GGTTCTGTGCTGACCTCATTTGAGGATG and bottom:  
AAAAGACTGGGTGAAATTTAGTTAAAG), Eα Y box probe 
(TCGACATTTTTCTGATTGGTTAAAAGTC) (Szabo et al., 1993) were used after 
labeling with 32P-dCTP. The probe (2.5x104cpm per reaction) was used along with 15μg 
of total cell extracts and 1ug poly diDC as described previously(Szabo et al., 1993). 
 For competitor-supershift assay, Batf binding to the AP-1 consensus probe(Echlin 
et al., 2000) was assessed by anti-FLAG supershift. Unlabeled probes from the IL-17a, 
IL-21 and IL-22 promoters were used to compete for Batf binding to the AP-1 consensus 
probe. Their sequences are provided below. Single stranded overhangs of the competitor 
oligos were not filled in. Sequences identified as competitors for Batf binding were used 
to determine the Batf consensus motif.  
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 For supershift analysis of the EMSA complexes formed on the AP-1 probe, whole 
cell extracts were prepared as above.  8μg whole cell extracts were incubated for 15min 
on ice with anti-Batf, anti-Fos (K25), anti-c-Jun (D), anti-c-Jun (N), anti-JunB (C11), 
anti-JunD (329), anti-ATF-1 (H60) and anti-ATF-3 (C-19)  (all Santa Cruz 
Biotechnology) before 2.5x104cpm of the AP-1 consensus probe was added.  
To test whether Batf binding to the AP-1 probe requires stimulation DO11.10 transgenic 
CD4+ T cells were activated for 3 days with OVA, irradiated APCs, anti-IFNγ/IL-4/IL12, 
TGF-β and IL-6, followed by a period of 3 days rest in the presence of TGF-β and IL-6. 
Cells were left untreated or activated with PMA/ionomycin for 4 hrs before whole cell 
extracts were prepared and used in EMSA analysis as described above.  
  
CONSENSUS program for determination of Batf binding motif. Sequences of the 
proximal promoter regions of IL-17, IL-21, and IL-22 identified as competitors for Batf 
binding in the competitor-supershift EMSA assay were input into CONSENSUS version 
v6d(Hertz and Stormo, 1999).  Default program parameters were applied, except for 
searching the reverse complement of the input sequences (c2) and uniform background 
nucleotide frequencies. The program was searching potential motif lengths from 5 to 15 
using the expected frequency statistic (e-value) and the optimal motif length was 
determined as 7.  The corresponding weight matrix, with a sample size adjusted 
information content of 4.467, was chosen from the final cycle.  The enrichment of the 
binding motif in the input set was verified using PATSER v3e(Stormo et al., 1982).  
Using the numerically calculated cutoff score, 38/40 of the input training sequences were 
identified as containing the motif. 
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 Batf Chromatin immunoprecipitation (ChIP). ChIP was performed as previously 
described (Hatton et al., 2006) using an affinity purified anti-Batf rabbit polyclonal 
antibody prepared by Brookwood Biomedical (Birmingham, AL).  Briefly, chromatin 
was prepared from 1x107 CD4+ T cells isolated from C57BL/6 Batf +/+ mice stimulated 
under TH17 polarizing conditions with anti-CD3 (2.5μg/ml) and syngeneic splenic feeder 
cells, then restimulated or not at the indicated time points with PMA (50ng/ml) and 
ionomycin (750ng/ml) for 4 h.  For experiments assessing early binding of Batf to the 
DNA CD4+ T cells from Batf +/+ and Batf -/- 129SvEv mice were activated with anti-
CD3/CD28 coated beads under TH17 conditions for 24 hours, then processed for ChIP 
analysis. Immunoprecipitations were performed with 20 μg/ml anti-Batf rabbit polyclonal 
antibody using the Chromatin Immunoprecipitation (ChIP) Assay Kit from Millipore 
(Billerica, MA) according to the manufacturer’s recommendations.  Immunoprecipitated 
DNA released from cross-linked proteins was quantitated by real-time PCR as previously 
reported (Hatton et al., 2006), and was normalized to input DNA.  All real-time PCR 
primers and probes are provided below. The analyzed sites are denoted relative to the 
ATG start codons for the Il17a or Il17f gene. 
For ChIP analysis of the IL-21 and IL-22 promoters DO11.10 transgenic CD4+ T 
cells from Batf +/+ and Batf -/- were stimulated with OVA and APC for 3 days, rested for 3 
days before restimulation with PMA/ionomycin for 4h on day 5 and processing for ChIP 
as described above. Real time PCR analysis was performed using ABI SYBR Green 
master mix according to the manufacturer’s instructions on a Step One Plus (Applied 
31
Biosystems) using the relative standard curve method. Results were normalized to input 
DNA. Sequences of primers used in the analysis are provided below.  
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ChIP primers 
 
Primers              Chr. 1 location     5’FAM 3’ BHQ1 Probes                   
IL17a -97 (-97kb) 
5’ AAATGTGAGCCCCAGATCGA 3’          20,623,606-20,623,625    CTGCTGCTGTCCCAGGCACAGTTG   
5’ GGGACATTTTTTCCACCATGA 3’          20,623,652-20,623,672 
 
IL17a -60 (-60kb 
5’ TTGTCCCCTGGCTGTTCCT 3’                    20,661,177-20,661,247      CCTTATCCAGCTGTCTTTTTCTCT   
5’ GGGCTCCCCAAAAATTCACA 3’                 20,661,274-20,661,293 
 
 
IL17a -37 (-37kb) 
5’ GTCCCTCTGTTGTTTCCAAGGAT 3’           20,683,616-20,683,638      TCATTGAGTCCTTCCAGCAGAGATTTCAGG    
5’ GCCATTTCAGCCACTGTGAA 3’           20,683,671-20,683,690 
 
IL17a -15 (-15kb) 
5’ TGGCAAATGTTTTGTCAACCA 3’           20,705,507-20,705,527   TTCCTCGATTGCTGTCTACTCATC   
5’ CATGCAGCCTCTGCTTGAGA 3’                 20,705,554-20,705,573 
 
 
IL17a -5 (-5kb)    
5’ CGATACTTTTCAGTGACATCCGTTT 3’      20,715,852-20,715,876   ACTTGAAACCCAGTCAGTTGCTGACCTTGA    
5’ TGCTGACTTCATCTGATACCCTTAGA 3’   20,715,910-20,715,935 
 
 
IL17a promoter (-243 to -176)  
5’ GAACTTCTGCCCTTCCCATCT 3’           20,720,800-20,720,820   CCTTCGAGACAGATGTTGCCCGTCA  
5’ CAGCACAGAACCACCCCTTT 3’                 20,720,848-20,720,867 
 
IL17a +9.6 (+9.6kb) 
5’ ATTTAGGGCACAGGTGACATGA 3’          20,730,688-20,730,709   TGGTTCTCAAAGCATAAACCTCATTC  
5’ CCACTTCCCCGACCTCACTA 3’          20,730,738-20,730,757 
 
IL17a +23 (+23kb) 
5’ CAAATCCGTGTGCCTTCTGTT 3’          20,744,816-20,744,836   CTGCAGTGAGGAAGATGTTTCCAATGAGG  
5’ AGGTTGACTTCGTCCCTGTGA 3’              20,744,870-20,744,890   
 
IL17a +28 (+28kb) 
5’ GTGGCCTACTTCAGGCAGATG 3’          20,749,994-20,750,014    TGAGAAGCCAGCGTCGGGTCC   
5’ GGAGCCGATGAGAAGCATTC 3’               20,750,039-20,750,058 
 
IL17a +36 (+36kb) 
5’ AGATAATGTATCACACAGCCCTGAAG 3’  20,757,551-20,757,576    AGCCAGTGCCTTAATCCATTGGG   
5’ CATGGTTGTGAAGTTGGTGAGATG 3’      20,757,602-20,757,625 
 
IL17f promoter   (-408 to -340)  
5’ ACTGCATGACCCGAAAGCA 3’         20,774,671-20,774,688    AACCCACACGCAGAGCATGACAAGAG  
5’ TTTAATTCCCCCACAAAGCAA 3’          20,774,620-20,774,640 
 
IL17f  -7 (-7kb) 
5’ TTCCCTTTTCTGCCTTGCA 3’         20,782,972-20,782,990    ACGAAGCACAGGGCTGGGCC   
5’ TGTGTAACACGCAGAGTGGAATG 3’       20,783,017-20,783,039 
 
 
     Chr. 3 location 
IL21 promoter  (-529 to -382)  
5’ GCATAGTCATCACCCCATAAA 3’             37,131,996-37,132,016  
5’ TCAGAGAAGTAAACACAAACAC 3’            37,131,869-37,131,890 
 
    Chr. 10 location 
IL22 promoter (-600 to -417) 
5’ GCACAGAATATAGGACACGGGT      117,641,447-117,641,468 
5’ ACACAGTTTTCAAAGAAAGCCA               117,641,609 117,641,630 
 
 
 
 
33
IL-17a promoter Oligos Sequence 5' to 3'  
33-1-top-IL17a GCACCCAGCACCAGCTGATCAGGACGCG 
33-1-bot-IL17a GTTTGCGCGTCCTGATCAGCTGGTGCTG 
46-14-top-IL17a ACGAGGCACAAGTGCACCCAGCACCAGC 
46-14-bot-IL17a GATCAGCTGGTGCTGGGTGCACTTGTGC 
69-37-top-IL17a GCACTACTCTTCATCCACCTCACACGAG    
69-37-bot-IL17a TGTGCCTCGTGTGAGGTGGATGAAGAGT 
83-51-top-IL17a AAAGAGAGAAAGGAGCACTACTCTTCAT  
83-51-bot-IL17a GGTGGATGAAGAGTAGTGCTCCTTTCTC 
100-68-top-IL17a GTAGTAAAACCGTATAAAAAGAGAGAAA 
100-68-bot-IL17a GCTCCTTTCTCTCTTTTTATACGGTTTT 
119-87-top-IL17a ACGTAAGTGACCACAGAGGTAGTAAAA                                                         
119-87-bot-IL17a TACGGTTTTACTACCTCTGTGGTCACT 
140-106-top-IL17a GTCACCCCCCAACCCACTCTTGACGTAAGT      
140-106-bot-IL17a TGGTCACTTACGTCAAGAGTGGGTTGGGGG 
159-127-top-IL17a GAATCTTTACTCAAATGGTGTCACCCCC                            
159-127-bot-IL17a GGTTGGGGGGTGACACCATTTGAGTAAA 
169-137-top-IL17a TTTGAGGATGGAATCTTTACTCAAATGG                                       
169-137-bot-IL17a TGACACCATTTGAGTAAAGATTCCATCC 
187-155-top-IL17a GGTTCTGTGCTGACCTCATTTGAGGATG                                                         
187-155-bot-IL17a GATTCCATCCTCAAATGAGGTCAGCACA 
204-172-top-IL17a GCCCGTCATAAAGGGGTGGTTCTGTGCT                                                        
204-172-bot-IL17a AGGTCAGCACAGAACCACCCCTTTATGA 
215-183-top-IL17a AGACAGATGTTGCCCGTCATAAAGGGGT                                                       
215-183-bot-IL17a GAACCACCCCTTTATGACGGGCAACATC 
235-203-top-IL17a GCCCTTCCCATCTACCTTCGAGACAGAT         
235-203-bot-IL17a GCAACATCTGTCTCGAAGGTAGATGGGA 
250-217-top-IL17a GCATAGTGAACTTCTGCCCTTCCCATCTA                 
250-217-bot-IL17a GAAGGTAGATGGGAAGGGCAGAAGTTCAC 
266-234-top-IL17a GAAGTCATGCTTCTTTGCATAGTGAACT                                   
266-234-bot-IL17a GCAGAAGTTCACTATGCAAAGAAGCATG 
281-249-top-IL17a CTGTTCAGCTCCCAAGAAGTCATGCTTC                                                    
281-249-bot-IL17a GCAAAGAAGCATGACTTCTTGGGAGCTG 
302-269-top-IL17a CTGAATCACAGCAAAGCATCTCTGTTCAG                                                      
302-269-bot-IL17a GGGAGCTGAACAGAGATGCTTTGCTGTGA 
320-286-top-IL17a GTCCATACACACATGATACTGAATCACAGC                                                  
320-286-bot-IL17a GCTTTGCTGTGATTCAGTATCATGTGTGTA 
334-302-top-IL17a GCAGCTTCAGATATGTCCATACACACAT      
334-302-bot-IL17a GTATCATGTGTGTATGGACATATCTGAA 
349-317-top-IL17a GAGCCCAGCTCTGCAGCAGCTTCAGATA                 
349-317-bot-IL17a GGACATATCTGAAGCTGCTGCAGAGCTG 
370-337-top-IL17a GACTCACAAACCATTACTATGGAGCCCAG                                       
370-337-bot-IL17a CAGAGCTGGGCTCCATAGTAATGGTTTGT 
383-351-top-IL17a GAGACTGTCAAGAGACTCACAAACCATT                                                 
383-351-bot-IL17a ATAGTAATGGTTTGTGAGTCTCTTGACA 
400-368-top-IL17a AAAGTGTGTGTCACTAGGAGACTGTCAA                                                        
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400-368-bot-IL17a GTCTCTTGACAGTCTCCTAGTGACACAC 
416-384-top-IL17a GATCAAGTCAAAATTCAAAGTGTGTGTC                                                        
416-384-bot-IL17a CTAGTGACACACACTTTGAATTTTGACT 
433-401-top-IL17a GGTAGAAAAGTGAGAAAGATCAAGTCAA 
433-401-bot-IL17a GAATTTTGACTTGATCTTTCTCACTTTT 
445-413-top-IL17a GCCAGGGAATTTGGTAGAAAAGTGAGAA       
445-413-bot-IL17a GATCTTTCTCACTTTTCTACCAAATTCC 
464-432-top-IL17a GGGCAAGGGATGCTCTCTAGCCAGGGAA                             
464-432-bot-IL17a GCAAATTCCCTGGCTAGAGAGCATCCCT 
476-44-top-IL17a GTGGGTTTCTTTGGGCAAGGGATGCTCT                                         
476-44-bot-IL17a GCTAGAGAGCATCCCTTGCCCAAAGAAA 
497-465-top-IL17a GTTTACATACTAAGACATTGAGTGGGTT                                                         
497-465-bot-IL17a AAAGAAACCCACTCAATGTCTTAGTATG 
 
IL-21 promoter Oligos Sequence 5' to 3'  
33-1-top-IL21  GTCATCAGCTCCTGGAGACTCAGTTCTG  
33-1-bottom-IL21 GCCACCAGAACTGAGTCTCCAGGAGCTG 
55-22-top-IL21 GTGAGAACCAGACCAAGGCCCTGTCATCA 
55-22-bottom-IL21 GGAGCTGATGACAGGGCCTTGGTCTGGTT 
67-35-top-IL21 AGTCAGGTTGAAGTGAGAACCAGACCAA     
67-35-bottom-IL21 GGGCCTTGGTCTGGTTCTCACTTCAACC 
88-56-top-IL21 TAGCGACAACCTGTGCACAGTCAGGT 
88-56-bottom-IL21 GTTCAACCTGACTGTGCACAGGTTGT 
105-73-top-IL21 GATGAATAAATAGGTAGCCGTAGCGACA 
105-73-bottom-IL21 CAGGTTGTCGCTACGGCTACCTATTTAT 
120-88-top-IL21 GGCCTCTTCTTGAGGGATGAATAAATAG 
120-88-bottom-IL21 GCTACCTATTTATTCATCCCTCAAGAAG 
137-105-top-IL21 CTGCAATGGGAGGGCTTGGCCTCTTCTT 
137-105-bottom-IL21 GCCTCAAGAAGAGGCCAAGCCCTCCCAT 
150-118-top-IL21 AAAGATTTCCAGGCTGCAATGGGAGGGC 
150-118-bottom-IL21 GCCAAGCCCTCCCATTGCAGCCTGGAAA 
174-142-top-IL21 GTTACTCACACTCATCCACTATACAAAG  
174-142-bottom-IL21 GAAATCTTTGTATAGTGGATGAGTGTGA 
183-151-top-IL21 GAAAAACGAGTTACTCACACTCATCCAC 
183-151-bottom-IL21 GTATAGTGGATGAGTGTGAGTAACTCGT 
207-175-top-IL21 CACGTACACCTAGCCAATGGAAAAGAAA 
207-175-bottom-IL21 TCGTTTTTCTTTTCCATTGGCTAGGTGT 
221-189-top-IL21 TGCCCCCACACGCACACGTACACCTAGC 
221-189-bottom-IL21 CATTGGCTAGGTGTACGTGTGCGTGTGG 
240-208-top-IL21 TGTGGACTCTATCCATCCCTGCCCCCAC 
240-208-bottom-IL21 TGCGTGTGGGGGCAGGGATGGATAGAGT 
254-222-top-IL21 GATGGGGCACATTTTGTGGACTCTATCC 
254-222-bottom-IL21 GGGATGGATAGAGTCCACAAAATGTGCC 
266-234-top-IL21 GTCTAAGATGCAGATGGGGCACATTTTG  
266-234-bottom-IL21 GTCCACAAAATGTGCCCCATCTGCATCT 
279-247-top-IL21 GTCTCTTTTTCCTGTCTAAGATGCAGAT 
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279-247-bottom-IL21 GCCCCATCTGCATCTTAGACAGGAAAAA 
304-272-top-IL21 GCTGAAAACTGGAATTCACCCATGTGTC  
304-272-bottom-IL21 AAAGAGACACATGGGTGAATTCCAGTTT 
314-282-top-IL21 CTTGGTGAATGCTGAAAACTGGAATTCA 
314-282-bottom-IL21 ATGGGTGAATTCCAGTTTTCAGCATTCA 
334-303-top-IL21 GACACACACACACACACACACCTTGGTG 
334-303-bottom-IL21 GCATTCACCAAGGTGTGTGTGTGTGTGTG 
361-328-top-IL21 GCCACACACACACACACACACACACACA 
361-328-bottom-IL21 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 
383-351-top-IL21 GAAATCTGACGGTGCCTCCTGTGCCACA 
383-351-bottom-IL21 GTGTGTGTGGCACAGGAGGCACCGTCAG 
395-363-top-IL21 GTTTACTTCTCTGAAATCTGACGGTGCC 
395-363-bottom-IL21 CAGGAGGCACCGTCAGATTTCAGAGAAG 
410-378-top-IL21 GATCAAAGTGTTTGTGTTTACTTCTCTG 
410-378-bottom-IL21 GATTTCAGAGAAGTAAACACAAACACTT 
422-390-top-IL21 TGCAGAGCAAAAGATCAAAGTGTTTGTG 
422-390-bottom-IL21 GTAAACACAAACACTTTGATCTTTTGCT 
447-415-top-IL21 GACAAACCAGGTGAGGTGCCAGGGATGC 
447-415-bottom-IL21 GCTCTGCATCCCTGGCACCTCACCTGGT 
463-429-top-IL21 GCCTTTATGACTGTCAGACAAACCAGGTGA 
463-429-bottom-IL21 GCACCTCACCTGGTTTGTCTGACAGTCATA 
476-445-top-IL21 GTCATTGCAGAAGTGCCTTTATGACTGT 
476-445-bottom-IL21 GTCTGACAGTCATAAAGGCACTTCTGCA 
494-462-top-IL21 GCCATGCCGCTGCTTTACTCATTGCAGA 
494-462-bottom-IL21 GCACTTCTGCAATGAGTAAAGCAGCGGC 
509-477-top-IL21 AAAGTTCCAATAAAGGCCATGCCGCTGC 
509-477-bottom-IL21 GTAAAGCAGCGGCATGGCCTTTATTGGA 
525-493-top-IL21 AGTCATCACCCCATAAAAAGTTCCAATA 
525-493-bottom-IL21 GCCTTTATTGGAACTTTTTATGGGGTGA 
543-511-top-IL21 GGTTCAGTCAAAAAGCATAGTCATCACC 
543-511-bottom-IL21 TATGGGGTGATGACTATGCTTTTTGACT 
558-526-top-IL21 AATGGAGTACAGGATGGTTCAGTCAAAA 
558-526-bottom-IL21 ATGCTTTTTGACTGAACCATCCTGTACT 
578-546-top-IL21 GTAACCTCTTCCATCATTGCAATGGAGT 
578-546-bottom-IL21 CCTGTACTCCATTGCAATGATGGAAGAG 
604-573-top-IL21 GCCCATCATTTAATTCTTCCTAAGAAG 
604-573-bottom-IL21 GGTTACTTCTTAGGAAGAATTAAATGA 
618-586-top-IL21 AGGTTAGAAAACTAGCCCATCATTTAAT 
618-586-bottom-IL21 GAAGAATTAAATGATGGGCTAGTTTTCT 
639-607-top-IL21 AGGATCTAAAATACTCTTGCTAGGTTAG 
639-607-bottom-IL21 GTTTTCTAACCTAGCAAGAGTATTTTAG 
657-625-top-IL21 GCACCCTTACAAAAAGATAAGGATCTAA 
657-625-bottom-IL21 GTATTTTAGATCCTTATCTTTTTGTAAG 
678-646-top-IL21 TGGAAGCAAATCCTATTTTAACACCCTT 
678-646-bottom-IL21 TTTGTAAGGGTGTTAAAATAGGATTTGC 
705-672-top-IL21 GCTATTTAAAGATACACTGGTGAAAATTG 
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705-672-bottom-IL21 GCTTCCAATTTTCACCAGTGTATCTTTAA 
718-686-top-IL21 AGGCACCATTAGTGCTATTTAAAGATAC 
718-686-bottom-IL21 CCAGTGTATCTTTAAATAGCACTAATGG 
736-704-top-IL21 GTTACATAAAGTGTCAGGAGGCACCATT 
736-704-bottom-IL21 GCACTAATGGTGCCTCCTGACACTTTAT 
754-722-top-IL21 GTATTTACAATCCATATTGTTACATAAA 
754-722-bottom-IL21 GACACTTTATGTAACAATATGGATTGTA 
775-743-top-IL21 AGTTCATCAAAACTGTTTATTGTATTTA 
775-743-bottom-IL21 GATTGTAAATACAATAAACAGTTTTGAT 
792-760-top-IL21 GAGCACGCTGTCTACTTAGTTCATCAAA 
792-760-bottom-IL21 ACAGTTTTGATGAACTAAGTAGACAGCG 
 
IL-22 promoter oligos Sequence 5' to 3'  
33-1-top-IL22  AGTTATCAACTGTTGACACTTGTGCGAT 
33-1-bottom-IL22 CAGAGATCGCACAAGTGTCAACAGTTGA 
48-16-top-IL22 ACAGGCTCTCCTCTCAGTTATCAACTGT 
48-16-bottom-IL22 TGTCAACAGTTGATAACTGAGAGGAGAG 
69-37-top-IL22 TTGCCTTTTGCTCTCTCACTAACAGGCT 
69-37-bottom-IL22 AGGAGAGCCTGTTAGTGAGAGAGCAAAA 
85-53-top-IL22 TGCTCCCCTGATGTTTTTGCCTTTTGCT 
85-53-bottom-IL22 GAGAGAGCAAAAGGCAAAAACATCAGGG 
107-75-top-IL22 GTACCATGCTACCCGACGAACATGCTCC 
107-75-bottom-IL22 TCAGGGGAGCATGTTCGTCGGGTAGCAT 
123-91-top-IL22 GACAATCATCTGCTTGGTACCATGCTAC 
123-91-bottom-IL22 GTCGGGTAGCATGGTACCAAGCAGATGA 
146-114-top-IL22 AGGTAAGCACTCAGACCTCTACAGACAA 
146-114-bottom-IL22 GATGATTGTCTGTAGAGGTCTGAGTGCT 
160-128-top-IL22 AGAGACACCTAAACAGGTAAGCACTCAG 
160-128-bottom-IL22 GAGGTCTGAGTGCTTACCTGTTTAGGTG 
181-149-top-IL22 TCTGCCTCTCCCATCACAAGCAGAGACA 
181-149-bottom-IL22 TTAGGTGTCTCTGCTTGTGATGGGAGAG 
193-161-top-IL22 AAAAGCAGCAACTTCTGCCTCTCCCATC 
193-161-bottom-IL22 CTTGTGATGGGAGAGGCAGAAGTTGCTG 
214-182-top-IL22 CCTGGTGTCCCGATGGCTATAAAAGCAG 
214-182-bottom-IL22 AGTTGCTGCTTTTATAGCCATCGGGACA 
233-201-top-IL22 GTCACAATACCAAAAAAACCCTGGTGTC 
233-201-bottom-IL22 ATCGGGACACCAGGGTTTTTTTGGTATT 
252-220-top-IL22 AATGTCTGATGTCATATCATTCACAATA 
252-220-bottom-IL22 TTTGGTATTGTGAATGATATGACATCAG 
267-235-top-IL22 GACTGGAAATTAGATAATGTCTGATGTC 
267-235-bottom-IL22 GATATGACATCAGACATTATCTAATTTC 
293-261-top-IL22 GTGGTTAGGTACTTCTCAGAAGACAGGA 
293-261-bottom-IL22 TCCAGTCCTGTCTTCTGAGAAGTACCTA 
305-273-top-IL22 TGGCCTCCTATGGTGGTTAGGTACTTCT 
305-273-bottom-IL22 TTCTGAGAAGTACCTAACCACCATAGGA 
329-297-top-IL22 GGAAGGCTTGGAGGTGGTGTCTTGTGGC 
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329-297-bottom-IL22 AGGAGGCCACAAGACACCACCTCCAAGC 
340-309-top-IL22 GCTCTCAAGGTGGGAAGGCTTGGAGGTG 
340-309-bottom-IL22 GACACCACCTCCAAGCCTTCCCACCTTG 
366-334-top-IL22 GTGACGTTTTAGGGAAGACTTCCCATCT 
366-334-bottom-IL22 TTGAGAGATGGGAAGTCTTCCCTAAAAC 
380-348-top-IL22 TGTTGGCCCTCACCGTGACGTTTTAGGG 
380-348-bottom-IL22 GTCTTCCCTAAAACGTCACGGTGAGGGC 
405-373-top-IL22 CTGGGATTTGTGTGCAAAAGCACCTTGT 
405-373-bottom-IL22 GGCCAACAAGGTGCTTTTGCACACAAAT 
420-388-top-IL22 GTGTTTAGAAGATTTCTGGGATTTGTGT 
420-388-bottom-IL22 TTTGCACACAAATCCCAGAAATCTTCTA 
497-465-top-IL22 AATAGCTACGGGAGATCAAAGGCTGCTC 
497-465-bottom-IL22 GAGTAGAGCAGCCTTTGATCTCCCGTAG 
518-486-top-IL22 CCGTGACCAAAACGCTGACTCAATAGCT 
518-486-bottom-IL22 CCCGTAGCTATTGAGTCAGCGTTTTGGT 
528-495-top-IL22 GAAAATGAGTCCGTGACCAAAACGCTGAC 
528-495-bottom-IL22 ATTGAGTCAGCGTTTTGGTCACGGACTCA 
536-504-top-IL22 GTTGGTGGGAAAATGAGTCCGTGACCAA 
536-504-bottom-IL22 GCGTTTTGGTCACGGACTCATTTTCCCA 
540-506-top-IL22 TGAAGTTGGTGGGAAAATGAGTCCGTGACC 
540-506-bottom-IL22 GTTTTGGTCACGGACTCATTTTCCCACCAA 
547-513-top-IL22 GAATCTATGAAGTTGGTGGGAAAATGAGTC 
547-513-bottom-IL22 TCACGGACTCATTTTCCCACCAACTTCATA 
558-527-top-IL22 TAAAGAGATAAGAATCTATGAAGTTGGT 
558-527-bottom-IL22 GTCCCACCAACTTCATAGATTCTTATCT 
574-543-top-IL22 GTATTTCTGGTCACTTCTAAAGAGATAA 
574-543-bottom-IL22 GATTCTTATCTCTTTAGAAGTGACCAGA 
595-563-top-IL22 GAATATAGGACACGGGTCTTTTATTTCT 
595-563-bottom-IL22 TGACCAGAAATAAAAGACCCGTGTCCTA 
612-580-top-IL22 GCTTATTTCAAAGCACAGAATATAGGAC 
612-580-bottom-IL22 CCCGTGTCCTATATTCTGTGCTTTGAAA 
628-596-top-IL22 CCAAGTTTTCATTATGGCTTATTTCAAA 
628-596-bottom-IL22 TGTGCTTTGAAATAAGCCATAATGAAAA 
650-619-top-IL22 GATTTTAAAAATTGAAATAATCTCCAAG 
650-619-bottom-IL22 GAAAACTTGGAGATTATTTCAATTTTTA 
662-630-top-IL22 AGAGATATAATTATTTTAAAAATTGAAA 
662-630-bottom-IL22 GATTATTTCAATTTTTAAAATAATTATA 
684-652-top-IL22 GGATTCCATATACTAAAAAAATAGAGATA 
684-652-bottom-IL22 GATTATATCTCTATTTTTTTAGTATATGG 
700-668-top-IL22 AGCTAGTTATAGTTTAGGATTCCATATA 
700-668-bottom-IL22 TTTAGTATATGGAATCCTAAACTATAAC 
 
Ap-1 consensus probe(Echlin et al., 2000) Sequence 5' to 3'  
Top  AGCTTCGCTTGATGAGTC 
Bottom GCCGACTGAGTAGTTCGC 
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RORE element(Yang et al., 2008) Sequence 5' to 3'  
Top GAAAGTTTTCTGACCCACTTTAAATCA 
        Bottom    CTTTAACTAAATTTCACCCAGTCTTTT 
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CHAPTER 3 
Batf expression, deletion and T cell specific overexpression of Batf 
 
Batf is highly expressed in effector T cells 
To identify new candidate genes that might regulate CD4+ effector T cell 
development and maintenance we performed a gene expression profiling experiment 
using microarray analysis. We compared gene expression patterns of naïve T cells to T 
helper cells (TH1, TH2 and TH17), Treg cells and a variety of other immune and non-
immune tissues. We hypothesized that genes with highly restricted expression across an 
array of tissues likely exhibit important regulatory functions in the cell types of 
expression. Thus, we were interested in identifying transcription factors with TH cell 
specific expression and we found the basic leucine zipper transcription factor ATF-like 
(Batf) (Dorsey et al., 1995) to be highly expressed in effector TH1, TH2 and TH17 cells, 
expressed at lower levels in naïve T cells and B cells and at essentially basal levels in 
other tissues (Figure 1).   
Batf is a transcription factor that is located in an evolutionary conserved cluster of 
genes that likely stems from a gene duplication event and contains multiple AP-1 family 
members (Rasmussen et al., 2005) (Figure 2a). Batf3 (p21-SNFT, JDP1), the highly 
homologous gene duplication of Batf (Iacobelli et al., 2000) (Figure 2b), also exhibited a 
very restricted expression pattern in our gene expression profiling experiment (Hildner et 
al., 2008), indicating that these two genes might exert regulatory functions in very 
specific cell types. Batf and Batf3 are highly conserved between species, with murine 
Batf being about 96% homologous to the human protein (Figure 3). The restricted 
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expression pattern of Batf in effector T cells and its high degree of evolutionary 
conservation lead us to hypothesize that Batf likely plays an important role in CD4+ 
effector T cells.  
Batf and Batf3 are basic leucine zipper (bZIP) proteins that are members of the 
AP-1 family that includes Jun, Fos, Musculoaponeurotic fibrosarcoma (MAF) and 
activating transcription factor (ATF) (Table 1). bZIP proteins are characterized by a C-
terminal leucine zipper and a basic domain. The leucine zipper mediates dimerization and 
the fully functional dimer binds to the DNA via the N-terminal basic region (Vinson et 
al., 2006) (Figure 4). Most AP-1 proteins contain defined transcriptional activation 
domains (TADs), but some, including Batf and Batf3, are composed only of a basic 
region and leucine zipper and lack obvious TADs.  Batf can inhibit AP-1 dependent 
luciferase activity in vitro and in vivo, as well as cellular transformation by Fos (Thornton 
et al., 2006; Williams et al., 2001; Iacobelli et al., 2000; Bower et al., 2004; Echlin et al., 
2000). Batf and Batf3 form heterodimers with Jun but not Fos proteins (Echlin et al., 
2000; Dorsey et al., 1995; Iacobelli et al., 2000) and are thought to function as 
endogenous repressors of AP-1 activity, by forming transcriptionally inert complexes 
with Jun proteins that exhibit identical DNA binding specificity as the Jun/Fos complex 
(Echlin et al., 2000; Thornton et al., 2006; Williams et al., 2001).  
AP-1 family proteins regulate T cell differentiation and cytokine production (Hess 
et al., 2004). In TH cells AP-1 proteins are differentially expressed and exhibit distinct 
functions.  JunB is predominantly expressed in TH2 but not TH1 cells, whereas JunD and 
c-Jun levels are similar in both subsets (Rincon et al., 1997). Jun B has been shown to 
promote TH2 differentiation, whereas JunD seems to generally inhibit cytokine 
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production by T cells (Li et al., 1999; Hartenstein et al., 2002; Meixner et al., 2004). In 
addition to Jun family members c-Maf regulates IL-4 production in TH2 (Ho et al., 1996) 
and transgenic overexpression of MafK suppresses T cell proliferation (Yoh et al., 2001). 
In conclusion, AP-1 family members play distinct roles in effector T cell development 
and maintenance and controlling AP-1 activity during T helper cell differentiation is vital 
for balancing pathogen specific effector responses.  
AP-1 proteins directly regulate many cytokine promoters in effector T cells, often 
in cooperation with other transcription factors (Macian et al., 2001). The IL-2 promoter is 
the most extensively studied cytokine promoter regulated by AP-1 proteins in 
conjunction with NFAT (Garrity et al., 1994; Jain et al., 1992). Interestingly, Batf3, the 
closely related AP-1 family member of Batf, can inhibit IL-2 promoter reporter assays 
(Iacobelli et al., 2000), indicating the potential of these small AP-1 proteins to regulate 
effector cytokine production. Therefore, we hypothesized that Batf might regulate T 
effector cell differentiation by modulating AP-1 signaling. 
 
Deletion of Batf by homologous recombination 
To assess the role of Batf in T cells, we generated Batf -/- mice by homologous 
recombination (Figure 5). This approach deletes exons 1 and 2 of Batf which contain the 
basic region and most of the leucine zipper. Correctly targeted clones were identified by 
Southern Blot analysis and the neomycin resistance cassette was deleted in vitro using a 
cre- recombinase expressing adenovirus. Batf -/- mice were born at normal Mendelian 
frequencies and germline transmission was confirmed by Southern Blot (Figure 5b). The 
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lack of Batf protein in Batf -/- mice was confirmed by Western Blot analysis using 
antibodies specific for Batf (Figure 5c).   
First, we assessed the development of the major lymphoid and myeloid lineages 
in Batf -/- mice. Batf -/- mice had no abnormalities in thymus or spleen cellularity, and 
lymph node development (Figure 6). The development of CD4+ and CD8+ T cells in 
thymus, spleen or lymph nodes was normal (Figure 7a). To assess whether Batf -/- T cells 
had abnormalities in their homeostatic activation, we stained T cells from Batf +/+ and 
Batf -/- mice with antibodies to the activation markers CD44 and CD25. We found similar 
expression of CD44 and CD25 on Batf +/+ and Batf -/- T cells (Figure 7b).  Despite 
reported severe reduction of NKT cell development following transgenic overexpression 
of Batf under control of the lck-promoter (Williams et al., 2003; Zullo et al., 2007), we 
found normal  NKT cell development in Batf -/- mice (Figure 7c).   
Batf -/- mice had normal B cell development in the spleen and bone marrow 
(Figure 8). We analyzed the development of B cells in the bone marrow as defined Hardy 
and colleagues using the surface markers B220, BP1, CD43, CD24, IgM and IgD (Hardy 
and Hayakawa, 2001). Within the B220+CD43hi cells the percentages of BP-1-CD24- 
(Hardy fraction A), BP-1-CD24+ (Hardy fraction B), and BP-1+CD24+ (Hardy fraction C) 
subsets were similar between Batf +/+ and Batf -/- mice. Within the B220+ CD43- cells the 
percentages of IgM-IgD- (Hardy fraction D), IgM+IgDlo (Hardy fraction E), and 
IgMloIgDhi (Hardy fraction F) were similar between Batf +/+ and Batf -/- mice (Figure 8b). 
Likewise, the frequency of splenic immature B cells (AA4.1+ B220+), Transitional 1 
(B220+IgMhiIgDlo), Transitional 2 (B220+IgMhi, IgDhi) and mature B cells (AA4.1-B220+; 
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B220+IgMloIgDhi) was similar between Batf +/+ and Batf -/- mice (Figure 8a) indicating 
normal development and homeostasis of B cells.  
Next, we assessed the development of conventional splenic dendritic cell (cDC) 
subsets, plasmacytoid dendritic cells and neutrophils in the absence of Batf.  cDCs were 
identified as CD11chi cells and further subdivided into CD4+ DCs and CD8+ DCs, 
identified as CD11chiCD4+CD8- and CD11chiCD4-CD8α+ respectively (Figure 9a).  
CD8+ DCs were further identified as CD11chiCD8α+ Dec205+ (Figure 9b).  All cDC 
subsets were present at normal ratios in Batf -/- mice compared to Batf +/+ mice. Similarly, 
plasmacytoid dendritic cells (pDC), identified as CD11b-CD11cloB220+Gr1+, were 
present at normal ratios in Batf -/- mice (Figure 9b). Neutrophils, identified as 
CD11b+Gr1hi cells, developed normally in Batf -/- mice although we observed a small but 
consistent increase in the frequency of splenic neutrophils (Figure 10a). This increase 
could be due to a cell intrinsic role of Batf in regulating neutrophil development or 
homeostasis, or alternatively be secondary to irregular neutrophil homing in response to 
imbalanced T cell cytokine production (Ye et al., 2001; Stark et al., 2005; Tan et al., 
2008). To distinguish these possibilities, we assessed splenic neutrophils in Rag2-/- mice, 
which are deficient in B cells, T cells and NKT cells. We found no differences in 
neutrophil numbers in 5 week old mice, however found a similar increase of neutrophils 
in 14 week old Batf -/-Rag2-/- mice compared to Batf +/+Rag2-/- mice (Figure 10b). These 
data indicate a cell-intrinsic role of Batf in neutrophil development or homeostasis rather 
than abnormal neutrophil homing in response to T cell cytokines. Further analysis will be 
necessary to determine the potential function of Batf in neutrophils.  
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T cell specific overexpression of Batf 
To facilitate studies pertaining to the function of Batf in T cells and test the affect 
of Batf overexpression on T cell differentiation we generated transgenic mice, expressing 
an N-terminally FLAG-tagged version of Batf. This N-FLAG-Batf was cloned under the 
control of the CD2 promoter (Zhumabekov et al., 1995) (Figure 11a). Transgene 
expression was confirmed by Western blot with an antibody specific to the FLAG epitope 
(Figure 11b). These mice were further crossed to DO11.10 T cell receptor (TCR) 
transgenic animals to facilitate T cell differentiation studies.  
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Figure 1. Batf is highly expressed in CD4+ effector T cells. 
The relative expression of Batf in the indicated tissues was determined by Affymetrix gene 
microarray.  The data are presented in arbitrary units and reflect normalized and modeled 
expression values generated using DNA-Chip analyzer (dChip) software. 
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 Batf3 MSQGPPAVSVLQRSVDAPGNQPQSPKDDDRKVRRREKNRVAAQRSRKKQT
 Batf MPHSSDSSDSSFSRSPPPGKQDSS--DDVRKVQRREKNRIAAQKSRQRQT
*.:.. : .       .**:* .*  ** ***:******:***:**::**
 Batf3  QKADKLHEEHESLEQENSVLRREISKLKEELRHLSEVLKEHEKMCPLLLC
 Batf QKADTLHLESEDLEKQNAALRKEIKQLTEELKYFTSVLSSHEPLCSVLAS
****.** * *.**::*:.**:**.:*.***::::.**..** :*.:* .
 Batf3 PMN------FVQLRSDPVASCLPR---
 Batf GTPSPPEVVYSAHAFHQPHISSPRFQP
:     .    . **   
ATF3
JDP2 Batf
Batf3
53% 48%
Mouse chr. 1q
(human 1q)
Mouse chr. 12q
(human 14q)
a
b
Figure 2. Batf is located in a cluster of genes that arose from gene duplication.  
a, Representation of the gene cluster containing Batf, Batf3, ATF3 and JDP2 that likely 
stems from a gene duplication. The percentage of sequence homology between Batf and the 
closely related Batf3 is indicated. b, Amino acid sequence alignment of Batf and Batf3. Blue 
amino acids indicate the basic region, red amino acids indicate the leucine zipper.  
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h Batf MPHSSDSSDSSFSRSPPPGKQDSSDDVRRVQRREKNRIAAQKSRQRQTQK 
m Batf MPHSSDSSDSSFSRSPPPGKQDSSDDVRKVQRREKNRIAAQKSRQRQTQK 
           ****************************:********************* 
 
    h Batf ADTLHLESEDLEKQNAALRKEIKQLTEELKYFTSVLNSHEPLCSVLAAST 
    m Batf ADTLHLESEDLEKQNAALRKEIKQLTEELKYFTSVLSSHEPLCSVLASGT 
           ************************************.**********:.* 
 
    h Batf PSPPEVVYSAHAFHQPHVSSPRFQP 
    m Batf PSPPEVVYSAHAFHQPHISSPRFQP 
           *****************:******* 
 
Figure 3. 96% sequence homology of human and mouse Batf.  
Amino acid sequence alignment of the human and mouse Batf proteins. Stars indicate 
identical amino acids, double dots indicate conservative changes, single dots indicate non-
conservative changes.   
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Family 
 
 
Name 
 
 
Dimers 
 
 
DNA binding element 
 
C/EBP 
C/EBPα, C/EBPβ, 
C/EBPγ, C/EBPδ, 
C/EBPε, CHOP, 
HP8 
homo- and 
heterodimers 
C/EBP (5’-ATTGCGCAAT-3’) 
CRE, PAR 
CREB 
 
ATF-1, CREB, 
CREM Ia, CREM Ib 
 
Homodimers CRE (5’-TGACGTCA-3’) 
OASIS 
OASIS, CREB-H, 
CREB3, CREB4, 
AC022173 
homodimers CRE 
ATF-6 ATF-6, ATF-6β, ZF (Zhangfei), XBP-1 homodimers 
 
CRE 
ATF/CREB-like 
 
ATF-2 
 
ATF-2, ATF-7, CREBPA 
 
homo- and 
heterodimers 
CRE 
ATF/CREB-like 
ATF-3 ATF-3, JDP2 heterodimers CRE ATF/CREB-like 
ATF-4 
 
ATF-4, ATF-4L1, ATF-5 
 
homo- and 
heterodimers 
CRE 
ATF/CREB-like 
Jun 
 
Jun, JunB, JunD 
 
homo- and 
heterodimers TRE (5’TGAGTCA-3’) 
Fos 
 
Fos, FosB, Fra1, Fra2 
 
heterodimers TRE (5’TGAGTCA-3’) 
Batf 
 
Batf, 
Batf3 (p21-SNFT,JDP1) 
 
heterodimers TRE (5’TGAGTCA-3’) 
smMaf MafG, MafK, MafF homo- and heterodimers 
TRE (5’TGAGTCA-3’) 
ATF/CREB-like 
 
lgMaf cMaf, MafB, MafA, NRL heterodimers 
TRE (5’TGAGTCA-3’) 
ATF/CREB-like 
 
CNC 
 
BACH1, NFE2L1, 
NFE2L2, NFE2L3, 
BACH2 
 
heterodimers AP-1 like palindromes (5’-T/CGCTGAC/GTCAT/C-3’) 
PAR 
 
DBP, HLF,TEF, NFIL3 
 
homodimers PAR (5’-ATTACGTAAT-3’) 
 
Table 1. The basic leucine zipper family of proteins (Vinson et al., 2002). 
Grouping of human bZIP proteins into families based on their dimerization properties and 
sequence homology of the leucine zipper region. 
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N-terminal
Leucine Zipper
major
groove
minor
groove
heptad
Figure 4. Ribbon diagram of the X-ray crystallography structure of a bZIP homodimer. 
Representation of a dimer of two basic leucine zipper proteins (blue helix) bound to the DNA. 
The N-terminal DNA recognition helix (basic region) lies in the major groove of the DNA. An 
almost invariant leucine (red) present every two turns of the C-terminal α-helix that forms the 
leucine zipper and mediates protein-protein interactions. 
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ba
c
+/+ -/-
Batf
β-Actin
-/-+/+ +/-
14 kb
9 kb
Exon
Neo
1 2 3
B B
B
B BamHI site homology arm
prA prB
B B
Neo
B
14.3kb
9kb2kb
Southern Blot probe
Targeting construct
Batf genomic locus
Targeted allele
22.4kb locus
loxP
B B
9kb
Neo deleted targeted allele
TK
Figure 5. Targeting of the Batf locus by homologous recombination. 
a, The endogenous genomic Batf locus, targeting construct and the mutant allele before and 
after cre-mediated deletion of the neomycin (neo) cassette are shown.  Restriction enzyme 
digestion of the genomic locus with BamHI results in a 14.3kb wild type fragment detected 
by Southern Blot probes A and B; in the targeted allele, probe A detects a 2kb and probe B 
detects a 9kb fragment. In the neomycin-deleted targeted allele, BamHI digestion results in a 
9kb fragment that is detected by both the 5’ and 3’ Southern Blot probes (probes A and B 
respectively). The neo cassette was deleted by in vitro treatment with a Cre-recombinase 
expressing Adenovirus.  b, Southern Blot analysis of targeted Batf alleles.  Probe A was 
used to hybridize BamHI digested genomic DNA from the indicated genotypes resulting from 
Batf +/- intercrosses. c, No residual protein expression in Batf -/- mice.  Total splenocytes were 
activated under TH17 conditions for 3 days.  Equal cell numbers were subjected to Western 
Blot analysis using anti-Batf antibody.  The blot was stripped and reblotted with an antibody 
to β-actin to show equal protein loading 
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b
Batf -/-Batf +/+
superficial inguinal LN superficial inguinal LN
Figure 6. Thymus, spleen and lymph nodes develop normally in Batf -/- mice. 
a, Total cell numbers of thymus (n=11) and spleen (n=17) from 8-10 week old Batf +/+ and 
Batf -/-  mice are shown (horizontal bars indicate mean cell numbers).  b, Batf +/+ and Batf -/-  
mice were injected with Evans Blue dye solution into each hind foot pad.  1.5h later 
superficial inguinal lymph nodes were visualized using a dissecting microscope. Data are 
representative of 2 independent experiments. 
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Figure 7. Normal T cell development in Batf -/- mice. 
a, Thymus, spleen and lymph nodes from Batf +/+ and Batf -/- mice were analyzed for the 
surface expression of CD4 and CD8 by flow cytometry.  The percentages of CD8+, CD4+ and 
CD4+CD8+  T cells were similar between Batf +/+ and Batf -/- mice.  b, Batf +/+ and Batf -/- 
splenic CD4+ and CD8+ cells were analyzed for the surface expression of the activation 
markers CD62L (left panel) and CD44 (right panel).  Data are presented as a histogram 
overlay of surface expression of CD62L and CD44.  c, Total splenocytes from Batf +/+ and 
Batf -/- mice were stained for CD3 in conjunction with unloaded or PBS57-loaded CD1d 
tetramers.  NKT cells are identified as CD3+CD1d-PBS57+. 
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Figure 8. Normal B cell development in Batf -/- mice. 
a, Total splenocytes were stained with antibodies to B220, AA4.1, IgM and IgD.  The 
percentages of immature B cells (AA4.1+ B220+), Transitional 1 (B220+IgMhiIgDlo), 
Transitional 2 (B220+IgMhi, IgDhi) or mature B cells (AA4.1-B220+; B220+IgMloIgDhi) were 
similar between Batf +/+ and Batf -/- mice.  b, Bone marrow cells were stained for the 
expression of B220, CD43 and either BP1 and CD24 or IgD and IgM.  The percentages of 
cells included in B220+CD43hi subsets: BP-1- CD24-, BP-1-CD24+, and BP-1+CD24+ (Hardy 
fractions A through C respectively) were similar between Batf +/+ and Batf -/- mice.  Also the 
percentages of B220+ CD43- subsets; IgM-IgD-, IgM+IgDlo, and IgMloIgDhi (Hardy fractions D 
through F respectively) were similar between Batf +/+ and Batf -/- mice. Numbers indicate 
percentage of cells in the indicated region. Data are representative of at least 2 independent 
experiments performed with multiple mice of each genotype. 
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Figure 9. Normal dendritic cell development in Batf -/- mice. 
a, Total splenocytes were stained with the indicated antibodies. Conventional splenic 
dendritic cell (cDC) were identified as CD11chi cells and further subdivided into CD4+ DCs 
and CD8+ DCs, identified as CD11chiCD4+CD8- and CD11chiCD4-CD8α+ respectively.  CD8+ 
DCs were further identified as CD11chiCD8α+ Dec205+.  b, Total splenocytes were stained 
with antibodies to CD11c, CD11b, Gr1 and B220.  Percentages of plasmacytoid dendritic 
cells (CD11b-CD11cloB220+Gr1+) were similar between Batf +/+ and Batf -/- mice.  Numbers 
indicate the percentage of live cells in each region. Data are representative of at least 2 
independent experiments performed with multiple mice of each genotype. 
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Figure 10. Batf -/- mice exhibit a slight increase in splenic neutrophils. 
a, Total splenocytes were stained with the indicated antibodies. Neutrophils were identified 
as Gr1hiCD11b+. Numbers indicate average percentages of neutrophils ± s.d. of four Batf +/+ 
and six Batf -/- mice from three independent experiments. b, Total spleen cells from Batf +/+, 
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Figure 11. Generation of CD2-N-FLAG-Batf transgenic mice. 
a, The FLAG-tagged Batf was cloned into the CD2 microinjection cassette (Zhumabekov et 
al., 1995).  b, Transgene expression in CD4+ and CD8+ splenocytes was assessed by anti-
FLAG western blot. (T cells: CD4+ and CD8+ magnetically purified splenocytes; control: 
splenocytes depleted of CD4+ and CD8+ cells; CD2-Batf: transgenic, WT: non-transgenic 
littermate) 
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CHAPTER 4 
Batf deficiency specifically ablates TH17 differentiation 
 
CD4+ Effector T cells orchestrate the immune response through the secretion of 
their signature cytokines. TH1 cells are the main players in cellular immunity against 
intracellular bacteria and viruses, whereas TH2 cells direct the humoral immune response 
to extracellular pathogens (Murphy and Reiner, 2002) and TH17 cells mediate acute 
inflammatory responses (Weaver et al., 2006). In addition to their importance in primary 
immune responses T helper cells produce large amounts of IL-2, required for the 
expansion of CD8+ memory T cells during secondary infections (Murphy and Reiner, 
2002; Weaver et al., 2006) and homeostasis of Treg cells (Lohr et al., 2006). Uncontrolled 
effector T cell responses can lead to the development of atopic diseases such as asthma 
(TH2 mediated) or the development of autoimmune diseases (TH1 and TH17 mediated) 
(Murphy and Reiner, 2002). Thus, balancing appropriate effector T cell development and 
cytokine production is critical during infections and determines the outcome of infectious 
and inflammatory responses.  
 
Normal TH1 and TH2 differentiation of Batf -/- T cells  
To test whether Batf regulates effector T cell differentiation we sorted naïve CD4+ 
T cells (CD4+CD62L+CD25-) from Batf +/+ and Batf -/-  mice. These T cells were activated 
with anti-CD3 and anti-CD28 antibodies either without the addition of cytokines and 
antibodies, or under TH1 (anti-IL-4, IFN-γ, IL-12) and TH2 (anti-IL-IFN-γ, anti-IL-12, IL-
4) conditions. On day 3, cells allowed to rest under skewing conditions. Since fully 
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differentiated T cells readily produce their effector cytokines upon TCR stimulation 
(Murphy and Reiner, 2002), we restimulated cells on day 7 with anti-CD3 and anti-CD28 
in the absence of exogenous cytokines and antibodies. Under these conditions, Batf -/- T 
cells produced similar levels of IL-4 and IFN-γ as Batf +/+ T cells (Figure 12a) as well as 
normal levels of IL-2. Additionally, Batf -/- T cells activated without skewing cytokines 
and antibodies produced similar IL-4 and IFN-γ as Batf +/+ T cells (Figure 12a). 
Therefore, Batf -/- T cells displayed normal TH1 and TH2 differentiation.  
 
Batf -/- T cells fail to produce IL-17 
In contrast to normal TH1 and TH2 differentiation, Batf -/- T cells activated under 
TH17 conditions showed a dramatic loss in IL-17 production (Figure 12b). Batf +/- T cells 
produced normal levels of IL-17 (Figure 13a). This remarkably selective defect in one 
particular pathway of T cell differentiation was somewhat surprising, since Batf was 
prominently expressed in TH1 and TH2 cells in our gene expression profiling experiment. 
To confirm these data, we performed Western blot analysis of naïve T cells and TH2 cells.  
Batf protein was low, but present in unactivated naïve T cells (Figure 14a).  Resting TH2 
cells expressed abundant Batf protein, which was further induced by activation (Figure 
14b). In resting T cells, Batf was present both in the nucleus and cytoplasm, but largely 
translocated to the nucleus after activation (Figure 15a and b). Notably, we found that 
Batf was present in T cells in two molecular weight species and that the lower molecular 
species was predominantly induced by activation (Figure 14). These observations are 
consistent with previous data demonstrating that Batf can be phosphorylated at serine 43 
in the DNA binding domain (Deppmann et al., 2003). This phosphorylation at Serine 43 
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has been shown to prevent DNA binding without affecting dimerization with Jun 
(Deppmann et al., 2003). Future experiments need to determine, whether phosphorylation 
of Batf plays a role for its function in T cells. Nevertheless, our data demonstrate that 
Batf protein is present in resting naïve and TH2 cells even though it seems to specifically 
regulate TH17 differentiation. 
 The loss of IL-17 production in Batf -/- T cells could conceivably result either 
from a disregulation in the production of TH17 suppressing cytokines or from a cell-
intrinsic requirement for Batf during TH17 differentiation. Multiple cytokines have been 
described in the literature to inhibit TH17 differentiation, including IFN-γ, IL-2, IL-4 and 
IL-10 (Harrington et al., 2005; Park et al., 2005; Laurence et al., 2007; Gu et al., 2008). 
We found that Batf -/- T cells produced similar levels of IL-2 compared to Batf +/+ T cells. 
Additionally, we observed no compensatory changes in the production of IFN-γ or IL-10 
in Batf -/- T cells (Figure 12b). These data indicate that Batf -/- T cell do not produce 
increased amounts of TH17 suppressing cytokines, and suggest that Batf might directly 
regulate transcriptional pathways controlling TH17 differentiation  
Proinflammatory cytokines such as IL-1β and TNFα (Veldhoen et al., 2006a), as 
well as activation by antigen presenting cells (APCs) instead of activation with antibodies 
to CD3 and CD28 (Ghilardi and Ouyang, 2007) augment TH17 development through 
unknown mechanisms. We tested whether addition of IL-1β and TNFα would rescue 
TH17 differentiation in Batf -/- T cells. As expected, IL-1β and TNFα increased IL-17 
production by Batf +/+ T cells compared to stimulation with IL-6 and TGF-β alone, 
however, failed to rescue IL-17 production in Batf -/- T cells (Figure 13b). Similarly, 
stimulation of DO11.10 TCR transgenic Batf +/+ and Batf-/- CD4+ T cells with OVA and 
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irradiated APCs under TH17 conditions did not restore IL-17 production in Batf-/- T cells 
(Figure 13a), even after repeated rounds of activation under TH17 conditions (Figure 
16a).  Thus, Batf-/- CD4+ T cells exhibit a severe loss of IL-17 production in vitro that 
cannot be overcome by the addition of proinflammatory cytokines.  
 
Batf regulates IL-17 production in CD8+ T cells 
Similarly to CD4+ T cells, IL-17 production can be induced in CD8+ T cells in 
response to IL-6 and TGF-β (Kryczek et al., 2007; Liu et al., 2007). The physiological 
role of IL-17 producing CD8+ T cells is not completely understood, but they have been 
isolated from tumors (Kryczek et al., 2007), have been implicated in a model contact 
hypersensitivity (He et al., 2006) and are capable of protecting mice against lethal 
influenza challenge (Hamada et al., 2009). 
To test whether IL-17 production in Batf -/- CD8+ T cells was normal, we activated 
total splenocytes from Batf +/+ and Batf -/- mice with anti-CD3 under TH17 conditions. Batf 
+/+ CD8+ T cells readily produced IL-17 under these conditions, however, Batf -/- CD8+ T 
cells activated under TH17 conditions showed loss of IL-17 production (Figure 16b), 
similar to CD4+ T cells. These data indicate a uniform loss of IL-17 production in Batf -/- 
conventional T cells.  
 
Overexpression of Batf increases IL-17 production by T cells 
If Batf was required to induce TH17 differentiation associated transcriptional 
programs, overexpression of Batf in T cells should promote IL-17 production. To 
examine Batf overexpression we generated transgenic mice expressing FLAG-tagged 
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Batf under the control of the CD2 promoter (Zhumabekov et al., 1995) (Figure 11a).  
Batf-transgenic DO11.10+CD4+ T cells were stimulated with OVA and APCs under TH17 
conditions and analyzed for cytokine production after restimulation with PMA/ionomycin 
on day 3. Batf-transgenic DO11.10+CD4+ T cells exhibited significantly increased IL-17 
production compared to non-transgenic control T cells (Figure 17a). Likewise, Batf-
transgenic CD8+ T cells produced increased amounts of IL-17 when activated under TH17 
conditions compared to non-transgenic CD8+ T cells (Figure 17b), indicating that Batf 
can promote IL-17 production in T cells.  
 
Batf regulates IL-17 production in vivo 
At mucosal surfaces, such as the intestinal lamina propria (LP), CD4+ T cells 
constitutively express IL-17 (Ivanov et al., 2006). At these sites, TH17 cells are thought to 
provide an immediate line of defense against certain bacteria (Ivanov et al., 2007). Indeed 
recent data suggests that the composition of the intestinal mucosa affects the balance 
between Treg and TH17 cells, thus influencing the equilibrium of intestinal tolerance 
versus immunity (Ivanov et al., 2008).  
Since Batf -/- T cells fail to produce IL-17 in vitro, we analyzed LP T cells for the 
production of IL-17. Batf -/- LP CD4+ T cells lacked IL-17 expression; however, 
spontaneous production of IFNγ was similar to Batf +/+ LP CD4+ T cells (Figure 18). 
Thus, Batf -/- LP CD4+ T cells do not exhibit a global deficiency in cytokine production.  
Collectively, these data demonstrate a uniform loss of IL-17 production in 
conventional Batf -/- T cells and show that Batf -/- T cells selectively fail to differentiate 
into TH17 cells.   
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Figure 12. Selective loss of IL-17 production in Batf -/- T cells. 
a, Naïve CD4+CD62L+CD25- T cells from Batf +/+ and Batf -/-  mice were activated with anti-
CD3/CD28 alone or under TH1 or TH2 conditions. Cells were restimulated on day 7 with anti-
CD3/CD28 for 24h and analyzed for IFN-γ and IL-4 production by intracellular staining. b, 
Naïve CD4+CD62L+CD25- T cells from Batf +/+ and Batf -/-  mice were activated under TH17 
(TGF-β plus IL-6) conditions. On day 7 (left panel) or day 3 (middle and right panels) cells 
were restimulated with PMA/ionomycin for 4h and stained for intracellular IL-17, IFN-γ, IL-2 
and IL-10. Data are representative of at least 2 independent experiments performed with 
multiple mice of each genotype. 
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Figure 13. Loss of IL-17 production in Batf -/- T cells. 
a, DO11.10+CD4+ T cells from Batf +/+, Batf +/- and Batf -/-  mice were activated with OVA and 
APCs under TH17 conditions for 3 days and stained for intracellular IL-17 and IFN-γ after 
restimulation with PMA/ionomycin.  b, Naïve CD4+CD62L+CD25- T cells from Batf +/+ and  
Batf -/- mice were activated with anti-CD3/CD28 under TH17 in the presence or absence of  
IL-1β and TNFα and stained for intracellular IL-17 and IFN-γ after restimulation with 
PMA/ionomycin.  Numbers represent the percentage of live cells in the indicated gates. Data 
are representative of at least 2 independent experiments performed with multiple mice of 
each genotype. 
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Figure 14: Batf protein is expressed in resting naïve T cells and TH2 cells. 
a, 1.5x106 cell equivalents of CD4+ T cells from Batf +/+ and Batf -/- mice were subjected to 
Western Blot analysis using anti-Batf antibody. The blots were stripped and reprobed with an 
antibody to β-actin to show equal protein loading. b, CD4+ T cells from Batf +/+ and Batf -/- 
mice were stimulated with anti-CD3/CD28 under TH2 conditions. On day 4, cells were left 
untreated or stimulated with PMA/ionomycin for 4h. Nuclear extracts from 0.5x106 cell 
equivalents were analyzed for Batf expression by Western Blot. The blots were stripped and 
reprobed with an anti-Lamin B antibody to show equal protein loading. Data are 
representative of 2 independent experiments. 
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Figure 15. Batf is located in the cytoplasm and nucleus of resting T cells. 
a, b, DO11.10+CD4+ T cells from CD2-N-FLAG-Batf transgenic (TG) or littermate control 
mice (WT) were cultured with OVA/APC under TH2 conditions. On day 7, cells were left 
untreated or stimulated with PMA/ionomycin for 4h, allowed to settle on poly-L-lysine treated 
slides and stained with antibodies to CD4 and FLAG. DAPI was used as nuclear stain.  
b, Higher magnification single cell representation of a cell in a.  c, Naïve DO11.10+CD4+ T 
cells from CD2-N-FLAG-Batf transgenic or littermate mice were stained as in a. Data are 
representative of 2 independent experiments. 
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Figure 16. Batf regulates IL-17 production in CD4+ and CD8+ T cells. 
a, CD4+ T cells from DO11.10 Batf +/+ and Batf -/- mice were activated with OVA and 
irradiated APCs under TH17 conditions.  3 days later, cells were split and allowed to expand 
for 4 days in the presence of TH17 inducing cytokines.  After 3 rounds of differentiation, cells 
were restimulated with PMA/ionomycin for 4h and analyzed for CD4, IFN-γ and IL-17 
expression by flow cytometry.  b, Total splenocytes from Batf +/+ and Batf -/- mice were 
stimulated under TH17 conditions for 3 days. Cells were restimulated with PMA/ionomycin 
and analyzed for IL-17 and IFN-γ expression by intracellular cytokine staining. Plots are 
gated on CD8+ cells. Data are representative of at least 2 independent experiments 
performed with multiple mice of each genotype. 
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Figure 17. Overexpression of Batf increases IL-17 production in CD4+ and CD8+ T cells. 
a, DO11.10+CD4+ T cells from CD2-N-FLAG-Batf transgenic (TG) or transgene-negative 
(WT) control mice were stimulated with OVA and APC under TH17 conditions.  3 days later, 
cells were restimulated with PMA/ionomycin and analyzed for CD4, IFN-γ and IL-17 
expression by flow cytometry.  b, Total splenocytes from CD2-N-FLAG-Batf transgenic (TG) 
or transgene-negative (WT) control were stimulated under TH17 conditions for 3 days. Cells 
were restimulated with PMA/ionomycin and analyzed for IL-17 and IFN-γ expression by 
intracellular cytokine staining. Plots are gated on CD8+ cells. . Data are representative of 2 
independent experiments. 
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Figure 18. Lamina propria CD4+ T cells in Batf -/- mice fail to produce IL-17. 
Small intestinal lamina propria cells were isolated from Batf +/+ and Batf -/- mice, stimulated 
with PMA/ionomycin for 3h and stained for IL-17 and IFN-γ. Plots are gated on CD4+ 
lymphocytes. Numbers indicate the percentage of live cells in each indicated gate.  Data are 
representative of 3 independent experiments performed with multiple mice of each genotype. 
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CHAPTER 5 
Batf -/- mice are completely resistant to EAE due to a T cell intrinsic defect 
 
While TH17 cells provide protection against bacteria at mucosal surfaces, they 
contribute to the pathology of multiple autoimmune diseases and disease models, 
including psoriasis, inflammatory bowel disease and experimental autoimmune 
encephalomyelitis (EAE) (Ouyang et al., 2008a). TH17 cells were first implicated as 
major players in EAE when mice deficient for the for the p19 subunit of IL-23, but not 
the p35 subunit of IL-12 were protected from EAE (Langrish et al., 2005; Park et al., 
2005; Yang et al., 2008). Since then, it has been recognized that IL-23 is required for 
EAE development because of its role in the maintenance of IL-17 producing T cells 
(Langrish et al., 2005). Additionally, mice deficient for transcription factors that control 
TH17 development, such as RORγt and IRF4, are protected from EAE (Ivanov et al., 
2006; Brustle et al., 2007). While these data clearly indicate the importance of TH17 cells 
in EAE pathogenesis, several studies have unsuccessfully addressed which TH17 effector 
cytokines are required for EAE development. Antibody blockade of IL-17A in the setting 
of Il17f-deficiency, or Il22 deficiency only minimally prevent EAE (Kreymborg et al., 
2007; Haak et al., 2009), implying the existence of other TH17 effector pathways that are 
required for EAE development.    
 
Batf -/- mice are resistant to MOG35-55-induced EAE 
Since Batf -/- T cells failed to develop into IL-17-secreting cells, we tested whether 
Batf -/- mice were susceptible to EAE. We immunized Batf  +/+ and Batf -/- mice with 
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myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35-55).  Eleven Batf +/+ mice 
(n=12) developed EAE, whereas no Batf -/- mice (n=13) developed any signs of disease 
within 40 days after immunization (Figure 19a).  During EAE, cytokine-producing CD4+ 
T cells infiltrate the CNS (central nervous system) leading to CNS inflammation and 
disease manifestations. CNS-infiltrating CD4+ T cells in Batf +/+ mice produced copious 
amounts of IL-17 and IFN-γ, at times of peak disease (day 10 after EAE induction). In 
contrast, fewer Batf -/-  CD4+ T cells infiltrated the CNS and produced no IL-17, but made 
similar amounts of IFN-γ as Batf  +/+ T cells (Figure 19b).   
Since fewer Batf -/- T cells infiltrated the CNS during EAE, disease resistance in 
Batf -/- mice might be due to a failure of T cells to traffic to the CNS. To address this 
question we tested whether IL-17-producing T cells were present in spleens of Batf -/- 
mice after EAE induction. Prior to disease onset, IL-17-producing CD4+ T cells were 
present in spleens from Batf +/+ but not Batf -/- mice (Figure 19c), indicating, that IL-17-
producing Batf -/- T cells do not solely fail to home to the CNS during EAE but do not 
develop.  
 
Batf -/- T cells do not preferentially develop into Foxp3+ cells during EAE 
The development of TH17 and Treg cells is reciprocally regulated (Bettelli et al., 
2006); the development of both lineages requires TGF−β but in the presence of IL-6 
TH17 cells develop preferentially. As a result, IL-6 deficient mice are resistant to EAE 
due to a compensatory increase in Foxp3+ T regulatory cells (Korn et al., 2007).  Thus, 
resistance of Batf -/- mice to EAE could conceivably result either from the loss of IL-17-
producing effector T cells, or from an increase in Treg cells.  We analyzed splenic T cells 
71
in Batf +/+ and Batf -/- mice for Foxp3 expression before immunization and 10 or 40 days 
after immunization with MOG35-55 (Figure 20a and b).  Batf -/- mice had lower basal 
numbers of splenic Foxp3+ T cells compared to Batf +/+ mice. More importantly, Batf -/- 
mice showed no statistically significant increase in Foxp3+ Treg cells after MOG35-55 
immunization (Figure 20a and b).  These data suggest that the resistance of Batf -/- mice to 
EAE results from an absence of TH17 cells rather than an increase in Treg cells.   
 
Batf -/- mice are protected from EAE due to a T cell intrinsic defect 
Since the MOG35-55 immunization model of EAE is primarily T-cell dependent 
(Wolf et al., 1996), the lack of TH17 development in Batf -/- mice likely explains disease 
resistance. This loss of TH17 development in Batf -/- mice could result either from a defect 
within T cells or a defect in antigen-presenting cells.  To distinguish these possibilities, 
we carried out an adoptive transfer study. We injected naïve Batf +/+ CD4+ T cells or PBS 
control buffer into mice before MOG35-55 immunization.  Batf -/- mice receiving PBS 
control buffer remained resistant to EAE as expected (Figure 21a).  In contrast, Batf -/- 
mice receiving naïve Batf +/+ CD4+ T cells developed severe EAE (Figure 21a and Table 
2). Although, Batf -/- mice that had received Batf +/+ T cells exhibited a slight delay in 
disease onset compared to Batf +/+ mice receiving Batf +/+ T cells, these differences are 
not statistically significant (Table 2). Notably, the transfer of Batf +/+ CD4+ T cells into 
Batf -/- mice also restored infiltration of the CNS by IL-17-producing CD4+ T cells 
(Figure 21b). 
Since Batf -/- T cells fail to develop into TH17 cells, we hypothesized that Batf -/- T 
cells might exhibit a protective function if transferred into Batf+/+ mice, conceivably 
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because of increased production of TH17 suppressing cytokines by Batf -/- T cells 
(Willenborg et al., 1996) or increased development of Foxp3+ Treg cells (Korn et al., 
2007). Therefore, we injected naïve Batf -/- CD4+ T into mice before MOG35-55 
immunization, however; the transfer of Batf -/- CD4+ T cells did not protect Batf +/+ mice 
from EAE development (Figure 21c).  
Collectively, our results indicate that the antigen-presenting environment in Batf -/- 
mice is permissive for TH17 development, and suggest that resistance to EAE in Batf -/- 
mice is due to a T cell-intrinsic defect in the generation of TH17 cells. 
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Figure 19. Batf -/- mice are resistant to EAE.   
a, Batf +/+ (n=12) and Batf -/- (n=13) mice were immunized with MOG33-35 peptide as described 
in Methods. Clinical EAE scores (mean ± s.e.m) representative of two independent 
experiments are shown.  b, 13 days after EAE induction, CNS infiltrating lymphocytes were 
stimulated with PMA/ionomycin for 4h, stained for intracellular IL-17 and IFN-γ and analyzed 
by flow cytometry.  Clinical scores are shown in parentheses. Data are representative of 2-3 
mice analyzed per group. c, Total splenocytes were isolated from Batf +/+ and Batf -/- mice 10 
days after EAE induction, stimulated with PMA/ionomycin for 3h and analyzed for IL-17 and 
IFN-γ expression by intracellular cytokine staining. All FACS plots are gated on CD4+ cells. 
Numbers for FACS plots indicate percentage of cells in each indicated gate. 
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Figure 20. Batf -/- mice show no compensatory increase in Foxp3+ cells during EAE. 
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induction were stained for the expression of CD4 and Foxp3 and analyzed by flow 
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Figure 21. Batf -/- mice are resistant to EAE due to a T cell-intrinsic defect. 
a, Batf +/+ and Batf -/- mice were injected with either control PBS buffer (n=5) or 1x107 Batf +/+ 
CD4+ T cells (n=6).  Four days later, mice were immunized with MOG35-55 peptide. b, Splenic 
and CNS infiltrating lymphocytes from experimental animals in a were stimulated with 
PMA/ionomycin for 4h and analyzed for IL-17 and IFN-γ production 40 days after EAE 
induction.  Genotypes and whether mice received PBS or CD4+ T cells are indicated, 
disease scores are given in parentheses.  FACS plots are gated on CD4+ cells and are 
representative of 2-3 mice analyzed per group.  Numbers in FACS plots indicate percentage 
of live cells in each region. c, Batf +/+ and Batf -/- mice were injected 1x107 Batf -/- CD4+ T cells 
(n=4). Four days later, mice were immunized MOG33-35 peptide. a, b, Mean clinical EAE 
scores representative of two independent experiments are shown. 
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Group Incidence Mean Max. Score Mortality Mean day of onset‡ 
PBS?Batf +/+ 5 of 5 (100%) 3.4 ± 0.7 1of 5 (20%) 12±0.8¶ 
PBS?Batf -/- 0 of 5 (0%) 0 0 of 13 (0%) NA 
Batf +/+CD4+?Batf +/+ 5 of 6 (83%) 3.0 ± 0.6 0 of 6 (0%) 13.6±2.3§¶ 
Batf +/+CD4+?Batf -/- 4 of 6 (66%) 2.4 ± 1.0 2 of 6 (33%) 15.5±1.7§ 
Table 2. Transfer of Batf +/+ CD4+ T cells restores EAE in Batf -/- mice. 
Batf +/+ and Batf -/- mice were injected with either control PBS buffer (n=5) or 1x107 Batf +/+ 
CD4+ T cells (n=6).  Four days later, mice were immunized with MOG35-55 as described in 
Methods.  Mean maximum score of disease was calculated and is presented ± s.e.m.  
‡ Mean day of onset is presented as mean ± s.d. Only animals positive for disease were 
included in the analysis. § not significant (p=0.215). ¶ not significant (p=0.232). NA, not 
applicable. 
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CHAPTER 6 
Batf controls the expression of a subset of IL-6 induced genes 
 
TH17 cells differentiate in response to the cytokines IL-6 and TGF-β (Bettelli et 
al., 2006; Korn et al., 2007; Nurieva et al., 2007; Wei et al., 2007; Zhou et al., 2007; 
Manel et al., 2008) but also require IL-21 and IL-23 for their full development (Korn et 
al., 2007; Nurieva et al., 2007; Wei et al., 2007; Langrish et al., 2005; Veldhoen et al., 
2006a). IL-6, IL-21 and IL-23 each activate STAT3 (Ghilardi and Ouyang, 2007), which 
is required for TH17 differentiation and binds directly to the Il17 promoter (Laurence et 
al., 2007; Yang et al., 2007; Mathur et al., 2007).  
Combined signals from IL-6 and TGF-β induce the expression of the retinoid acid 
related nuclear orphan receptor (ROR) RORγt (Ivanov et al., 2006), in a STAT3 
dependent manner(Yang et al., 2007; Harris et al., 2007). RORγt is sufficient to induce 
IL-17 production in wild type T cells and RORγt deficiency blocks TH17 differentiation 
in vitro (Ivanov et al., 2006). RORγt has been considered the main regulator of TH17 
cells, similar to T-bet and Gata3 in TH1 and TH2 cells respectively. However, residual IL-
17 production can be observed in RORγt deficient T cells in vivo after EAE induction 
(Ivanov et al., 2006). Since RORα and RORγt double deficient do not exhibit this 
residual IL-17 production, RORα has been suggested to cooperate with RORγt during 
TH17 differentiation at the level of Il17 transcription (Yang et al., 2008). However, 
RORα deficiency only mildly affects IL-17 production (Yang et al., 2008), indicating 
that RORα is dispensable for TH17 differentiation and that RORγt and RORα exhibit 
mere functional redundancy. More strikingly, Irf4-/- T cells exhibit an absolute block in 
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TH17 development and decreased expression of RORγt. However, overexpression of 
RORγt in Irf4-/- T cells only partially restores IL-17 production (Brustle et al., 2007), 
indicating that IRF4 likely regulates additional factors during TH17 differentiation. More 
recently, RUNX1 and RORγt have been suggested to synergize to induce Il17 
transcription (Zhang et al., 2008a). The aryl hydrocarbon receptor (AHR), a ligand-
dependent transcription factor, specifically regulates IL-22 but not IL-17 production in T 
cells (Veldhoen et al., 2008; Quintana et al., 2008) although AHR ligands are necessary 
for optimal differentiation of TH17 cells (Veldhoen et al., 2009). Thus, multiple 
transcription factors have been suggested to control TH17 differentiation, although it is 
unclear how they cooperate to induce TH17 differentiation.  
 
Proximal IL-6 receptor signaling and TGF-β signaling is normal in Batf -/- T cells 
Since Batf is a transcription factor, it could control TH17 differentiation either by 
regulating the expression of components of the IL-6 or TGF-β signaling pathways (Korn 
et al., 2007; Nurieva et al., 2007), or by regulating the induction of their downstream 
target genes. To distinguish these alternatives, we determined whether these signaling 
pathways were intact in Batf -/- T cells. IL-6 receptor expression on Batf -/- CD4+ T cells 
was normal (Figure 22a). Further, treatment with IL-6 induced normal levels of STAT3 
phosphorylation in both CD4+ and CD8+ Batf -/- T cells (Figure 22b), indicating that 
proximal IL-6 receptor signaling is normal in Batf -/- T cells.  
Proximal TGF-β signaling also appeared intact based on normal induction of 
Foxp3 in response to TFG-β in Batf -/- CD4+ T cells (Figure 23a).  Foxp3 inhibits RORγt 
function, and one of the roles of IL-6 during TH17 differentiation is to suppress Foxp3 
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expression (Bettelli et al., 2006). Batf -/- T cells failed to fully downregulate Foxp3 in 
response to IL-6 when cultured under TH17 conditions (Figure 23a). Neutralization of IL-
2 abrogated increased Foxp3 expression in Batf -/- T cells, but failed to restore IL-17 
production (Figure 23b). Since TGF-β signaling and proximal IL-6 signaling are intact in 
Batf -/- T cells, these data suggest that Batf may be required for the regulation of genes 
downstream of IL-6. 
 
Batf is required for the induction of IL-21 
Consistent with a requirement for Batf for the expression of genes downstream of 
IL-6, induction of IL-21, an early target of IL-6 signaling in CD4+ T cells (Zhou et al., 
2007), was significantly reduced in Batf -/- CD4+ T cells activated under TH17 conditions 
(Figure 24a).  Consistently, Batf -/- CD4+ T cells activated under TH17 failed to induce IL-
23 receptor expression (Figure 24b), which requires IL-21 signaling (Zhou et al., 2007). 
This reduced production of IL-21 could potentially explain the absence of TH17 
development in Batf -/- T cells, since autocrine IL-21 is required for TH17 development 
(Korn et al., 2007; Nurieva et al., 2007; Wei et al., 2007).  However, addition of IL-21 
failed to rescue TH17 development in Batf -/- T cells (Figure 24c). This absence of IL-17 
production in the presence of exogenous IL-21 could be due to a failure to express IL-21 
receptor or IL-21 signaling components. However, proximal IL-21 signaling was intact, 
since Batf -/- CD4+ T cells showed normal levels of IL-21-induced STAT3 
phosphorylation (Figure 24d). These data indicate normal expression and function of the 
IL-21 receptor signaling machinery and suggest that Batf regulates additional factors 
besides IL-21 during TH17 differentiation.    
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 Batf controls the expression of a subset of IL-6-induced genes 
To identify additional Batf target genes, we performed DNA microarrays and 
quantitative real time polymerase chain reaction (qRT-PCR) comparing gene expression 
of Batf +/+ and Batf -/- T cells activated in the presence or absence of IL-6 and/or TGF-β in 
combination with neutralizing antibodies to IL-6 and/or TGF-β as indicated (Figure 25).  
To allow identification of Batf-dependent TH17-specific genes, anti-IL-2 antibody was 
added to avoid contamination with genes specifically expressed in Foxp3+ cells (Figure 
23a and b). This analysis identified additional Batf-dependent genes, some of which are 
known to regulate TH17 development (Figure 25 and Figure 27a and b). Batf-dependent 
genes included RORγt (Zhou et al., 2007), RORα (Yang et al., 2008), the aryl 
hydrocarbon receptor (AHR) (Veldhoen et al., 2008; Kimura et al., 2008; Quintana et al., 
2008), IL-22 (Liang et al., 2006) and IL-17.  In contrast, IRF4 (Brustle et al., 2007) 
(Figure 27a) and SOCS gene expression (Figure 26b) were unchanged in Batf -/- T cells.  
Notably, early induction of RORγt and RORα in Batf -/- T cells occurred normally but the 
expression of these genes was not maintained at 62h after stimulation (Figure 27c), 
indicating that Batf is required for the sustained expression of RORγt and RORα rather 
than their early induction.  
Finally, microarray analysis indicated that Batf was required for the expression of 
a subset of IL-6-induced genes (Figure 25) but not TGF-β-induced genes (Figure 26a). 
Specifically, we found that genes induced in response to either IL-6 alone or IL-6 plus 
TGF-β in wild type cells clustered into genes that displayed either Batf-dependent or 
Batf-independent expression (Figure 25). However, Batf deficiency did not affect the 
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expression of genes induced in response to TGF-β alone (Figure 26a). Notably, Batf 
deficiency did not globally affect IL-6-induced responses in all tissues, since IL-6-
induced liver acute phase responses appeared normal in Batf -/- mice (Figure 28). These 
data indicate that Batf is required for the induction of numerous IL-6-dependent genes in 
T cells.  
 
RORγt only partially restores IL-17 production in Batf -/- T cells 
Since RORγt has been suggested to act directly on the Il17 promoter (Ichiyama et 
al., 2008; Zhang et al., 2008b), we tested whether forced RORγt expression would rescue 
TH17 development in Batf -/- T cells.  First, when Batf +/+ T cells were activated without 
cytokine additions, forced RORγt overexpression by retrovirus led to 38% IL-17 
production, compared to only 1.6% IL-17 production induced by the control retrovirus 
(Figure 29a and c). This was consistent with previous studies demonstrating that RORγt 
is sufficient to induce IL-17 production (Ivanov et al., 2006; Brustle et al., 2007).  In 
contrast, in Batf -/- T cells activated under these conditions forced RORγt expression led 
to only 5.7% IL-17 production (Figure 29a and c).  When T cells were activated in TH17-
inducing conditions, forced RORγt expression induced only 7.6% IL-17 production in 
Batf -/- T cells, compared to 50% IL-17 production in Batf +/+ T cells (Figure 29b and c).  
Thus, RORγt only partially restores TH17 differentiation in Batf -/- T cells.  
RORα, a nuclear receptor related to RORγt has been suggested to cooperate with 
RORγt during TH17 differentiation, since mice deficient in RORα and RORγt do not 
exhibit the residual IL-17 production that is observed in the absence of RORγt alone 
(Yang et al., 2008). However, RORα deficient T cells show only a mild reduction in IL-
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17 production (Yang et al., 2008). Even though this indicates that RORα is dispensable 
for TH17 differentiation we felt that the potential functional cooperation between RORγt 
and RORα might explain the absence of IL-17 production in Batf -/- T cells, since the 
expression of both factors is reduced in the absence of Batf. Thus, we tested whether 
overexpression of both RORα and RORγt would rescue IL-17 production in Batf -/- T 
cells. Even overexpression of both RORα and RORγt failed to fully restore IL-17 
production in Batf -/- T cells (Figure 29d). 
Since RORγt overexpression only partially restored IL-17 production in the 
absence of Batf, Batf and RORγt might cooperate to induce IL-17 production. To test this 
we carried out dual retroviral infections (Figure 30).  Forced expression of both Batf and 
RORγt in Batf -/- T cells induced 26% IL-17 production, compared to only 5% with 
RORγt alone, and 14% with Batf alone. These data suggest functional synergy between 
RORγt and Batf in inducing IL-17 production, and also suggest that Batf might directly 
regulate the transcription of Il17 and other TH17-specific genes. 
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Figure 22. Proximal IL-6 receptor signaling is normal in Batf -/- T cells. 
a, Splenocytes from Batf +/+ and Batf -/- mice were stained with antibodies to CD4 and IL-6 
receptor (IL-6R).  A histogram overlay of IL-6R expression on CD4+ cells of the indicated 
genotypes is shown.  b, Magnetically purified Batf +/+ and Batf -/- CD4+ T cells (left) and CD8+ 
T cells (right) were stimulated with anti-CD3/CD28 in the presence of IL-6 for the indicated 
times and stained with an antibody to phospho-STAT3 (black lines) by intracellular staining 
as described in Methods.  Untreated cells (grey lines) served as negative control. 
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Figure 23.  Normal TGF-β signaling in Batf -/- T cells. 
a, Naïve CD4+CD62L+CD25- T cells from Batf +/+ and Batf -/- mice were stimulated with TGF-β 
or TGF-β plus IL-6 for 3 days.  Cells were stained for Foxp3 and analyzed by flow cytometry. 
b, Naïve CD4+CD62L+CD25- T cells from Batf +/+ and Batf -/- mice were stimulated with TGF-β 
plus IL-6 in the presence of a neutralizing antibody to IL-2 for 3 days. Cells were stained for 
Foxp3, IL-17 and IFN-γ and analyzed by flow cytometry. Numbers for FACS plots indicate 
the percentage of live cells in each region.  Data are representative of at least 2 independent 
experiments performed with cells from multiple mice of each genotype. 
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Figure 24. Exogenous IL-21 fails to rescue IL-17 production in Batf -/- T cells. 
a, IL-21 expression in T cells 3 days after activation with anti-CD3 and anti-CD28 under 
TH17 conditions was determined by quantitative real time PCR (left) and ELISA (right).  
b, IL-23 receptor (IL-23R) expression in T cells 3 days after activation with anti-CD3/CD28 
under TH17 conditions was determined by quantitative real time PCR. qRT-PCR data are 
normalized to HPRT and presented as percent expression relative to Batf +/+ cells (mean + 
s.d. of 3 individual mice). c, Naive CD4+CD62L+CD25- T cells were activated as in a in the 
presence or absence of IL-21 and stained for intracellular IL-17 and IFN-γ.  d, Magnetically 
purified Batf +/+ and Batf -/- CD4+ T cells were stimulated with anti-CD3/CD28 in the presence 
of IL-21 for the indicated times and stained with an antibody to phospho-STAT3 (black lines) 
by intracellular staining.  Untreated cells (grey lines) served as a negative control. 
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Figure 25. Batf controls the expression of a subset of IL-6 dependent genes in during T cell 
differentiation. 
Gene expression microarray analysis of T cells activated with anti-CD3/CD28 for 72h with 
various combinations the indicated cytokines and antibodies. Shown are representative heat 
maps of genes at least 5-fold induced under TH17 conditions compared to neutral conditions 
in Batf +/+ T cells. Normalized and modeled expression values were generated and clustered 
using DNA-Chip analyzer (dChip) software. 
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Figure 26. Batf does not regulate expression of SOCS genes or genes induced by TGF-β 
alone 
a, b, Gene expression microarray analysis of T cells activated with anti-CD3/CD28 for 72h 
with various combinations the indicated cytokines and antibodies. a, A representative heat 
map of genes at least 5-fold induced by TGF-β compared to neutral conditions in Batf +/+ T 
cells is presented. b, Shown is a representative heat map of the expression of Suppressor of 
cytokine signaling (SOCS) genes in Batf +/+ and Batf -/- T cells. Normalized and modeled 
expression values were generated using DNA-Chip analyzer (dChip) software. 
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Figure 27. Batf is required for the expression of multiple TH17 associated genes and for 
sustained expression of RORγt and RORα. 
a, Batf +/+ and Batf -/- naïve CD4+CD62L+CD25- T cells were stimulated with anti-CD3/CD28 
under TH17 conditions for 72h and relative expression of RORγt, RORα, IL-22 and IRF-4 in T 
cells was analyzed by qRT-PCR.  b, CD4+ T cells from Batf +/+ and Batf -/-  mice were 
activated with anti-CD3/CD28 under TH17 conditions for 3 days, restimulated with 
PMA/ionomycin and stained for intracellular IL-17 and IL-22 expression.  c, Batf +/+ and  
Batf -/- naïve CD4+CD62L+CD25- T cells were stimulated with anti-CD3/CD28 under TH17 
conditions for 0, 8, 16, 24 and 62h and analyzed for expression of RORγt and RORα by 
qRT-PCR.  qRT-PCR data are normalized to HPRT and presented as percent expression 
relative to Batf +/+ cells (mean + s.d. of 3 individual mice). 
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Figure 28. Several aspects of the IL-6-induced liver acute phase response are normal in 
Batf -/- mice. 
a, Batf +/+ and Batf -/- mice were injected intraperitonally with either 0.3ug IL-6 or saline.  4h 
after injection the expression of the indicated acute phase proteins in liver was assessed by 
qRT-PCR. b, Relative expression of Batf in liver 4h after injection of mice with 0.3ug IL-6 or 
saline. qRT-PCR data is normalized to HPRT and presented in arbitrary units. Data 
represent mean + s.d. of 3 individual mice from independent experiments. 
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Figure 29. RORγt only partially restores IL-17 production in Batf -/- T cells. 
a, b, Batf +/+ and Batf -/- CD4+ T cells stimulated with anti-CD3/CD28 under the indicated 
conditions were either left untreated, infected with RORγt expressing IRES-GFP-retrovirus 
(RORγt-RV) or control retrovirus (GFP-RV). Cells were restimulated with PMA/ionomycin for 
4h and analyzed for GFP and IL-17 expression.  c, The percentage of IL-17 producing cells 
among stably infected (GFP+) cells treated as in a and b is depicted (mean + s.d. of 3 
independent experiments). d, Batf +/+ and Batf -/- CD4+ T cells stimulated with anti-CD3/CD28 
under TH17 conditions and infected with RORγt expressing IRES-GFP-retrovirus (RORγt-RV) 
and RORα expressing IRES-hCD4-retrovirus (RORα-RV) or control retrovirus. Cells were 
restimulated with PMA/ionomycin for 4h.  IL-17 expression in GFP+hCD4+ cells is shown. 
Numbers in FACS plots represent the percentage of live cells in each region. 
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Figure 30. Functional synergy of Batf and RORγt during TH17 differentiation. 
a, Batf -/- CD4+ T cells were stimulated with anti-CD3/CD28 under TH17 conditions and either 
infected with Batf-expressing IRES-GFP-retrovirus (Batf-RV), RORγt-expressing IRES-
hCD4-retrovirus (RORγt-RV) or both (bottom panel). As a control, cells were infected with 
empty-control retroviruses as indicated (top panel). On day 3, cells were restimulated with 
PMA/ionomycin for 4h and analyzed for IL-17 and IFN-γ expression.  Data are representative 
of 2 independent experiments.  Representative FACS plots shown are gated as indicated. 
Numbers represent percentage of live cells in each region. 
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CHAPTER 7 
Batf directly regulates the expression of TH17 associated cytokines 
 
Little is known about the transcriptional regulation of TH17 associated genes. 
RORγt has been suggested to bind directly to the proximal Il17 promoter and to 
conserved non-coding sequences upstream of the Il17 locus (Ichiyama et al., 2008; Zhang 
et al., 2008b; Akimzhanov et al., 2007). RORγt can induce Il17 promoter activity in 
reporter assays (Ichiyama et al., 2008; Zhang et al., 2008b) however, since RORγt 
deficient T cells show residual IL-17 production (Ivanov et al., 2006) other factors likely 
contribute to Il17 gene transcription. RUNX1 cooperates with RORγt at the Il17 promoter 
in reporter assays (Zhang et al., 2008b). Additionally, NFAT has been implicated in 
regulating Il17 transcription in humans (Liu et al., 2004). Notably, this study found no 
role for AP-1 transcription factors at the proximal Il17 promoter, however, promoter 
analysis was limited to EMSA binding of AP-1 factors to the -0.4kb proximal promoter.  
Since Batf -/- T cells failed to induce multiple TH17-associated genes and 
cytokines and RORγt overexpression only minimally restored IL-17 production in the 
absence of Batf, we hypothesized that Batf might regulate Il17 transcription directly.  
  
The proximal Il17 promoter is Batf-responsive 
To test whether Batf directly regulates Il17 expression, we first tested Il17 
promoter activity in primary Batf +/+ and Batf -/- T cells (Zhu et al., 2001) using a reverse 
strand retroviral reporter in which human CD4 (hCD4) marks viral infection and the Il17 
promoter drives GFP expression (Figure 31). On day 3 of activation under TH17 
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conditions we analyzed reporter activity in stably infected (hCD4+) cells. Under these 
conditions, Batf -/- CD4+ T cells showed considerably less reporter activity than Batf +/+ T 
cells (Figure 31). These data suggest that the 1kb proximal Il17 promoter is Batf-
responsive.  
 
Batf binds several regions in the Il17a/f locus  
To test whether Batf regulates Il17 promoter activity and gene expression through 
direct interactions, we next performed chromatin immunoprecipitation (ChIP) and 
elecrophoretic mobility shift assays (EMSA).  For ChIP analysis, we examined several 
highly conserved regions within the Il17a/f locus (Figure 32a) that we hypothesized to be 
putative regulatory regions due to their evolutionary sequence conservation.  By ChIP 
analysis, Batf specifically bound to two intergenic regions (+9.6kb and +28kb) as early as 
24h after activation (Figure 32c). By day 5 after stimulation, Batf showed strong binding 
to several intergenic regions (-5kb, +9.6kb and +28kb) and to the proximal Il17a and 
Il17f promoters (Figure 32b and d). Interestingly, Batf binding was only slightly 
augmented by cell stimulation (Figure 32b and d) indicating potential constitutive 
binding of Batf to the DNA in differentiated TH17 cells.  Notably, Batf binding to the 
distal conserved regulatory enhancer elements by ChIP was stronger than binding to the 
proximal promoter elements (Figure 32b and d) and occurred earlier during the course of 
T cell differentiation (Figure 32c). In summary, Batf binds multiple regions in the Il17a/f 
locus in the natural chromatin state during TH17 differentiation.  
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 Batf binds multiple sites in the proximal Il17, Il21 and Il22 promoters 
To further define Batf binding to the DNA we performed EMSA analysis by first 
testing an AP-1 consensus probe (Echlin et al., 2000) (TGAGTCA) for binding Batf in 
TH17 cells.  This probe formed two complexes in Batf +/+ TH17 cell extracts (Figure 33a, 
lane 1) that were strongly dependent on stimulation (Figure 33c, lanes 1 and 2).  Only the 
upper of these two complexes formed in extracts from Batf -/- T cells cultured under TH17 
conditions (Figure 33a, lane 2 and Figure 33c, lanes 3 and 4), suggesting the lower 
complex contains Batf.  Consistently, an anti-Batf antibody blocked the formation of the 
lower complex (Figure 33a, lane 5).  Using TH17 cell extracts derived from Batf-
transgenic mice expressing the FLAG-tagged version of Batf, we found that only the 
lower complex was specifically supershifted by an antibody to the FLAG epitope, but not 
by a control antibody (Figure 33a, lanes 7-12).  Formation of the upper complex was not 
affected by the anti-FLAG antibody.  Thus, Batf is present specifically within the lower 
complex of the two complexes that bind to the consensus AP-1 probe in TH17 cells.        
Since Batf was required for IL-17, IL-21 and IL-22 expression (Figures 24a, 25 
and 27a and b), we hypothesized that Batf bound to the promoters of these genes. To test 
this we preformed a “competitor supershift assay”. We used extracts derived from Batf-
transgenic TH17 cells in EMSA analysis on the AP-1 probe and identified the Batf 
containing complex using the anti-FLAG epitope antibody (Figure 34a, lane 4). We then 
used oligo sequences spanning the proximal promoters of Il17, Il21 and Il22 as 
competitors for the formation of this Batf containing complex (Figure 34b-d). This 
approach identified multiple potential Batf binding sites in all three cytokine promoters, 
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including the region in the Il17 promoter binding Batf in ChIP assays (-188 to -210) 
(Figure 32b and d), confirming the validity of our approach to identify bona fide Batf 
binding sites.   
Notably, one of the regions in the Il17 promoter (-155 to -187) binding Batf by 
EMSA overlaps with a ROR-responsive element (RORE) suggested to bind RORγt 
(Ichiyama et al., 2008). This region also contains a sequence (TGACCTCA) closely 
resembling an AP-1 consensus element (Echlin et al., 2000; Eferl and Wagner, 2003).  
When used as a competitor, this region (-155 to -187), but not the RORE element in the 
CNS-2 region of Il17 (Yang et al., 2008), inhibited the formation of both upper and lower 
EMSA complexes formed by the AP-1 probe (Figure 33a, lanes 3, 4).  Thus, the Il17 
promoter region between -155 and -187 interacts with complexes binding the AP-1 probe 
independently of its ability to bind RORs.   
More importantly, when this region (-155 to -187) was used as an EMSA probe, 
this element itself formed two complexes in extracts from Batf +/+ TH17 cells, which were 
both augmented by stimulation (Figure 33b, lanes 1-4).  Again, the lower complex was 
selectively inhibited by an anti-Batf antibody and only the upper of the two complexes 
formed in extracts from Batf -/- T cells cultured under TH17 conditions (Figure 33b, lane 2 
and 4), and an anti-Batf antibody blocked the formation of the lower complex (Figure 
33b, lane 9). In TH17 extracts from Batf-transgenic T cells only the lower complex was 
specifically supershifted by an antibody to the FLAG epitope (Figure 33b, lanes 11-14). 
To confirm binding of Batf to the Il21 and Il22 promoter regions in the context of 
natural chromatin, we performed ChIP analysis. Indeed, Batf bound to the Il21 and Il22 
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promoters by ChIP analysis (Figure 35a). Thus Batf binds to multiple regions in the 
proximal promoters of the Il17, Il21 and Il22 cytokine genes.  
 
The preferred Batf binding motif differs from a symmetric AP-1 consensus element 
We next wondered whether Batf containing transcriptional complexes exhibit 
identical DNA binding specificity as conventional AP-1 complexes, i.e. whether they 
bound consensus dyad symmetric AP-1 response elements (TGAN(N)TCA). Thus, we 
analyzed all Batf-binding sequences in the Il17, Il21 and Il22 promoters for the presence 
of a common Batf binding motif using the CONSENSUS program (Hertz and Stormo, 
1999). The derived sequence logo (Crooks et al., 2004) (Figure 35b) strongly resembles a 
canonical AP-1 motif at positions 1 through 3, but exhibits sequence variation in the 
remaining nucleotides, thus differing from the dyad symmetric AP-1 response element 
(TGAN(N)TCA).   
To potentially identify transcription factors that might cooperate with Batf, we 
used the CONSENSUS program to obtain information about alternative motifs enriched 
near the Batf binding sites by masking the regions matching the putative Batf binding 
motif. This approach identified no secondary motifs to be significantly enriched nearby 
Batf binding sites. As an alternative approach, we also used the MEME program 
(meme.sdsc.edu) in a similar manner with default parameters. MEME identified only one 
motif with significance (e-value of 8.3 e-7), which was essentially the same motif as 
found by CONSENSUS for Batf binding, containing the same core TGAGTG. Meme 
found two other motifs, CCTGTGC, which had an e-value of 1.1 e+4, and 
ACCAAACGCT, which had an e-value of 1.8 e+4. However, e-values for neither of 
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these motifs were considered significant. Thus, CONSENSUS found no significant 
enrichment of other sequence motifs or binding sites for other transcription factors in the 
vicinity of Batf binding elements.   
In summary, Batf-binding elements are distributed within the promoters of Il17, 
Il21 and Il22 and contain a motif that varies from the conventional AP-1 response 
element.  Even though we found no alternative motifs enriched near Batf binding sites, 
factors regulating Il17, Il21 and Il22 may act at sites located outside the regions 
examined, may have more degenerate target sequences, or may not be common to all 
cytokine promoters, unlike Batf, which appears common to all of these promoters.   
 
Batf preferentially dimerizes with JunB in the context of TH17 differentiation 
Finally, to test whether in TH17 cells Batf acts as a homo- or heterodimer with Jun 
as previously suggested (Echlin et al., 2000; Dorsey et al., 1995), we performed antibody-
supershift analysis of EMSA complexes.  We used antibodies to Fos (anti-pan-Fos 
antibody), Jun (anti-pan-Jun antibody, as well as antibodies to c-Jun, JunB and JunD), 
and antibodies to Batf, ATF1 and ATF3. 
The upper complex was specifically supershifted by pan-anti-Fos antibody.  The 
lower complex was specifically supershifted by both a pan-anti-Jun and anti-Batf 
antibodies. This suggests that the lower complex contains Batf and Jun proteins.  Using 
antibodies to individual Jun family proteins, we found that anti-c-Jun and anti-JunD only 
slightly affected the lower complex, whereas anti-JunB almost completely inhibited the 
lower complex (Figure 36). Also, antibodies to ATF1 or ATF3 two ATF, family 
members related to Batf and expressed in TH17 cells, had no effect on either complex. 
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cells that migrate faster on EMSA gels than the Fos-Jun AP-1 complex, producing the 
distinct lower complex. This is consistent with previous observations that Batf may 
interact with Jun family proteins (Dorsey et al., 1995; Echlin et al., 2000; Senga et al., 
2002).  
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Figure 31. The proximal Il17 promoter is Batf-responsive. 
a, Batf +/+ and Batf -/- CD4+ T cells cultured under TH17 conditions were infected with hCD4-
pA-GFP-RV-IL-17p reverse strand reporter virus (Zhu et al., 2001), in which hCD4 marks 
infected cells and the proximal Il17a promoter drives GFP expression.  On day 3, cells were 
restimulated with PMA/ionomycin. Plots are gated on hCD4+ cells and analyzed for GFP 
expression. 
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Figure 32. Batf binds multiple regions in the Il17a/f locus. 
a, Vista blot depicting the sequence conservation of the human and mouse Il17a/f gene loci. 
The locations of primers used for ChIP analysis are indicated and are denoted relative to the 
ATG for the Il17a or Il17f genes.  b, Batf +/+ and Batf -/- CD4+ T cells cultured with anti-CD3 
and APCs under TH17 conditions for 5 days were subjected to ChIP analysis of the indicated 
regions using anti-Batf antibody. c, Batf +/+ or Batf -/-CD4+ T cells were activated with anti-
CD3/CD28 under TH17 conditions for 24h, then subjected to ChIP analysis using anti-Batf 
polyclonal antibody as in b. d, Batf +/+ CD4+ T cells from C57Bl/6 mice were treated as in a. 
All ChIP data are presented as relative binding based on normalization to unprecipitated 
input DNA (mean + s.d. of 2 independent experiments). 
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Figure 33. Batf binds to the Il17a promoter by EMSA. 
a,b,  EMSA supershift analysis of whole cell extracts from total splenocytes activated with 
anti-CD3 under TH17 conditions for 3 days.  Binding to a consensus AP-1 probe 
(AGCTTCGCTTGATGAGTCAGCCG) (Echlin et al., 2000) (a, c) or the IL-17 (-155 to -187) 
probe (b) was analyzed.  (Batf +/+ (WT), Batf -/- (KO), CD2-N-FLAG-Batf transgenic (TG),  
IL-17(-155 to -187) and RORE probes were used as competitors). c, DO11.10+CD4+ T cells 
from Batf +/+ and Batf -/- littermates were activated with OVA and APCs under TH17 
conditions.  On day 7, cells were either left untreated or stimulated with PMA/ionomycin for 
4h. Whole cell extracts were analyzed for EMSA binding to the consensus AP-1 probe. 
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Figure 34. Identification of potential Batf binding sites in the Il17a, Il21 and Il22 promoters. 
a, Whole cell extracts from total splenocytes activated with anti-CD3 under TH17 conditions 
for 3 days were analyzed for binding to the AP-1 probe by EMSA supershift (CD2-N-FLAG-
Batf transgenic (TG)). b-d, EMSA analysis performed as in a, Batf containing complexes 
were identified by supershift with anti-FLAG antibody.  Sequences from the Il17a (b), Il21 (c) 
and Il22 (d) promoters were used as inhibitors of Batf containing complexes as described in 
Methods. Sequences of competitors used are supplied in Chapter 2. 
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Figure 35. Confirmation of Batf binding to the Il21 and Il22 promoters and identification of a 
Batf binding motif. 
a, Batf +/+ and Batf -/- CD4+ T cells were stimulated under TH17 conditions for 5 days. ChIP 
analysis was performed as described in methods. The analyzed sites are denoted relative to 
the ATG for the Il21 or Il22 genes. Data are presented as relative binding based on 
normalization to unprecipitated input DNA. b, WebLogo (Crooks et al., 2004) presentation of 
the 7-base Batf-binding motif identified by the CONSENSUS (Hertz and Stormo, 1999) 
program present in 38/40 Batf-binding regions of the Il17a, Il21 and Il22 promoters. The size 
of each indicated nucleotide is proportional to the frequency of its appearance at each 
position. 
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Figure 36. Batf preferentially binds JunB in TH17 cells. 
Total splenocytes from Batf +/+ and Batf -/- mice were activated with anti-CD3 under TH17 
conditions for 3 days. Whole cell extracts were analyzed by EMSA supershift for binding to 
the AP-1 consensus probe using antibodies to Batf, pan-Fos, pan-Jun, JunB, JunD, c-Jun, 
ATF-1 and ATF-2. 
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Chapter 8 
Discussion 
 
The studies presented here identify a critical requirement for Batf in TH17 
differentiation and TH17-mediated autoimmune disease. We found that the AP-1 protein 
Batf, which lacks a TAD, was highly expressed in T helper cells compared to various 
other immune cells and tissues. To study the role of Batf in T cells, we generated Batf 
deficient mice by gene targeting. Batf -/- mice show a highly selective defect in the 
differentiation of IL-17-producing T helper (TH17) cells. TH17 cells are a CD4+ T cell 
subset that coordinates inflammatory responses in host defense but are pathogenic in 
autoimmunity (Langrish et al., 2005; Park et al., 2005; Ivanov et al., 2006; Bettelli et al., 
2006; Brustle et al., 2007). We found that Batf -/- mice are completely resistant to 
experimental autoimmune encephalomyelitis due to the inability of Batf deficient T cells 
to differentiate into TH17 cells. Using gene expression analysis, we found that Batf -/- T 
cells fail to induce known TH17-specific transcription factors, such as RORγt, and the 
cytokine IL-21, required for TH17 differentiation.  Neither addition of IL-21 nor 
overexpression of RORγt fully restores IL-17 production in Batf -/- T cells, suggesting 
that Batf may be required directly for IL-17 transcription. We found that the Il17 
promoter is Batf-responsive, and upon TH17 differentiation, Batf binds to several 
conserved intergenic elements in the Il17a/f locus as well as to regions in the Il17, Il21 
and Il22 promoters. Using bio-computational methods we determined that the Batf-
binding element in the Il17, Il21 and Il22 promoters differs from canonical symmetric 
AP-1 elements. Using EMSA analysis we found that Batf forms heterodimers 
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preferentially with JunB during TH17 differentiation. These results demonstrate that the 
AP-1 factor Batf regulates previously unknown AP-1 target genes to control TH17 
differentiation and TH17-mediated autoimmune disease.  
 
Batf specifically controls TH17 differentiation 
We found that Batf -/- T cells specifically failed to differentiate into TH17 cells, 
while TH1 and TH2 differentiation was unaffected. Our results demonstrate that Batf -/- T 
cells do not exhibit increased production of cytokines that can suppress TH17 
differentiation, such as IL-2, IFN-γ, IL-4 or IL-10. Thus Batf deficiency does not lead to a 
general imbalance in cytokine production but rather Batf seems to directly affect TH17 
differentiation. Consistently, Batf deficiency abrogates IL-17 production in CD4+ and 
CD8+ T cells and the addition of exogenous TH17-promoting cytokines fails to rescue IL-
17 production in Batf -/- T cells.  Therefore, Batf -/- T cells exhibit a remarkably selective 
defect in TH17 differentiation.  
This selective defect in one particular pathway of TH differentiation was 
surprising since Batf was also expressed in TH1 and TH2 cells. Notably, we found that 
Batf was present in T cells in two molecular weight species and that the lower molecular 
weight species was predominantly induced by activation. The presence of two molecular 
weight species is consistent with previous observations that Batf can be phosphorylated at 
serine 43 in the DNA binding domain (Deppmann et al., 2003). Phosphorylation of Batf 
at serine 43 has been suggested to prevent DNA binding without affecting dimerization 
with Jun proteins (Deppmann et al., 2003), adding complexity to the regulation of AP-1 
signaling by Batf. Whether Batf is indeed subject to phosphorylation in T cells and 
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whether phosphorylation of Batf affects its function in T cells will have to be determined 
in future experiments. Nevertheless, the occurrence of a lower molecular weight species 
following activation of T cells suggests that dephosphorylation of Batf in response to T 
cell activation might regulate Batf function during T cell differentiation.  
While Batf is not the first transcription factor identified to regulate TH17 
differentiation, Batf is unique in that its effects are more specific to TH17 differentiation. 
Only four transcription factors have been shown to be required for TH17 development; 
IRF4, STAT3, RORγt, and RUNX1 (Laurence et al., 2007; Yang et al., 2007; Ivanov et 
al., 2006; Brustle et al., 2007; Zhang et al., 2008b). While RORα may influence TH17 
differentiation, RORα deficient mice show essentially normal TH17 development (Yang 
et al., 2008), indicating it is not required.  
Irf4-/- T cells have a complete block in TH17 differentiation; however, Irf4-/- T 
cells also show severe defects in TH2 development (Lohoff et al., 2002; Rengarajan et al., 
2002; Hu et al., 2002), plasmacytoid dendritic cell (pDC) and CD4+ dendritic cell 
development (Suzuki et al., 2004) as well as defects in plasma cell differentiation and B 
cell class switching (Sciammas et al., 2006). Unlike IRF4, we found no defects in other T 
helper lineages besides TH17. Batf -/- mice have normal pDC and CD4+ cDC 
development. Even though Batf -/- B cells show a defect in class switching that needs to 
be further defined (see Appendix 1), plasma cell differentiation occurs. Thus, B cell 
function is not globally affected in the absence of Batf, as is the case in Irf4-/- mice.  
STAT3 is activated immediately downstream of the IL-6 receptor and required at 
multiple stages of hematopoietic cell development. As a result STAT3-/- mice are not 
viable, and studying its role in T cells required the use of a specific Cre deletor strain. 
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Deletion of STAT3 during T cell development using an Lck-Cre deletor strain caused the 
loss of IL-6-induced proliferation of thymocytes (Takeda et al., 1998). Unlike STAT3, 
Batf does not globally affect IL-6 responses, evident by normal liver acute phase response 
in Batf -/- mice. Also, we found that Batf is not required for normal development of 
thymocytes, but functions only in the TH17 effector response, by regulating a distinct 
subset of IL-6-dependent genes.   
RORγt deficient mice lack lymph nodes and show some residual IL-17 production 
in vivo, with residual disease development in the EAE model (Sun et al., 2000; Ivanov et 
al., 2006). Unlike RORγt deficient mice, Batf -/- mice have normal lymphoid development 
and architecture and are completely resistant to EAE. Also, Batf regulates sustained 
expression of RORγt and is to our knowledge the first factor shown to directly regulate 
the expression of Il17, Il21 and Il22.  
RUNX1 is required at many stages of development and acts in multiple tissues 
and lineage decisions, being described recently to be required for the differentiation of 
haemogenic endothelium into blood cells (Lancrin et al., 2009). RUNX1 was analyzed in 
TH17 differentiation only by siRNA knockdown and by overexpression of a dominant 
negative in mature T cells (Zhang et al., 2008b). Unlike RUNX1, Batf -/- mice are viable, 
fertile, and show a selective defect in TH17 differentiation.  
In summary, Batf -/- T cells exhibit a surprisingly selective defect in TH17 
differentiation and the effects of Batf are more specific to TH17 differentiation than those 
of previously identified factors. Thus, Batf -/- mice provide an exceptional model system 
to selectively study the role of TH17 cells in T cell mediated immune responses and 
autoimmune diseases.  
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Batf -/- mice are completely resistant to EAE 
Batf -/- mice were completely resistant to the development of MOG35-55 -induced 
EAE due to defective TH17 development. The MOG35-55 immunization model of EAE is 
primarily T-cell mediated (Wolf et al., 1996). TH17 cells were first recognized as the 
major pathogenic T cell subset when mice deficient for the p19 subunit of IL-23, but not 
the p35 subunit of IL-12 were found to be protected from disease development (Langrish 
et al., 2005; Park et al., 2005; Yang et al., 2008). IL-23 is required for the maintenance of 
IL-17 producing T cells during EAE (Langrish et al., 2005). and mice deficient for 
transcription factors, such as RORγt and IRF4, that control TH17 development are 
protected from EAE (Ivanov et al., 2006; Brustle et al., 2007). However, RORγt deficient 
mice are only partially resistant to EAE and IL-17 production can be observed in RORγt-/- 
T cells in vivo after EAE induction (Ivanov et al., 2006). In contrast, Irf4-/- T cells exhibit 
an absolute block in TH17 development resulting in complete resistantance to EAE 
(Brustle et al., 2007). Intriguingly, the phenotype of Irf4-/- mice in EAE is markedly 
similar to the phenotype we observed in Batf -/- mice.  
TH17 and Treg cells develop via reciprocal pathways (Bettelli et al., 2006) and IL-
6-deficient mice are resistant to EAE due to a compensatory increase in Foxp3+ T 
regulatory cells in the absence of TH17 differentiation (Korn et al., 2007). Strikingly, we 
found no compensatory increase in the development of Foxp3+ Treg cells in Batf -/- mice 
during EAE, suggesting that Batf -/- mice are resistant to EAE due a selective defect in 
TH17 differentiation. Consistent with the absence of increased Treg cell development in 
the absence of Batf, the transfer of Batf -/- T cells into Batf +/+ mice did not protect against 
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EAE development. In contrast, using this same T cell transfer model, we found that the 
transfer of wild type T cells restored EAE development and TH17 development in Batf -/- 
mice, indicating that Batf -/- mice provide an antigen presenting environment permissive 
for TH17 development. Thus Batf -/- mice are protected from EAE due to a T cell intrinsic 
defect that prevents TH17 development, rather than a defect in T cell priming.  
Since the importance of TH17 cells in EAE pathogenesis is recognized, several 
studies attempted to address which TH17 effector cytokines are required for EAE 
development. IL-23 is critical for EAE development due to its role in maintaining TH17 
cells in vivo (Langrish et al., 2005); indicating the requirement for TH17 cells. However, 
IL-22 deficiency only minimally prevented EAE (Kreymborg et al., 2007) and antibody 
blockade of IL-17A in the setting of Il17f-deficiency also only minimally affects EAE 
development (Haak et al., 2009) implying the existence of other TH17 effector pathways 
that are required for EAE development. Since Batf -/- mice specifically lack the TH17 
lineage, they provide a model allow addressing which TH17 effector cytokines are 
required for EAE using adoptive transfer systems.  
In summary, the protective effect of Batf deficiency on EAE development is 
striking and very similar to the phenotype observed in Irf4-/- mice or mice that are either 
globally deficient in IL-6 signaling (Korn et al., 2008) or deficient in IL-6 signaling 
specifically in T cells (Korn et al., 2007).  Since TH1 and TH2 cell differentiation is 
normal in the absence of Batf, our studies provide strong support that TH17 cells are 
important mediators of EAE pathogenesis. Additionally, in contrast to Irf4-/- mice, which 
exhibit abnormal TH2 development, Batf -/- mice provide an excellent model system to 
selectively study the role of TH17 cells in T cell-mediated autoimmune disorders.  
111
Batf controls the expression of a subset of IL-6-induced genes 
 TH17 cells differentiate in response to TGF-β and the proinflammatory cytokine 
IL-6, and require IL-21 (Bettelli et al., 2006; Korn et al., 2007; Nurieva et al., 2007; Wei 
et al., 2007; Zhou et al., 2007; Manel et al., 2008). Our data demonstrate that proximal 
IL-6 receptor signaling, proximal IL-21 signaling and TGF-β signaling were normal in 
Batf -/- T cells. The TGF-β induced transcription factor Foxp3 inhibits RORγt function 
and thus TH17 differentiation (Zhou et al., 2008). IL-6 partly promotes TH17 
differentiation through the inhibition of Foxp3 (Bettelli et al., 2006). Since we found that 
Batf -/- T cells failed to fully downregulate Foxp3 in response to IL-6, Batf might function 
to inhibit Foxp3 expression in TH17 cells. This was again similar to what has been 
observed in Irf4-/- T cells, which also fail to downregulate Foxp3 in response to IL-6 
(Brustle et al., 2007). However, neutralization of IL-2 during TH17 differentiation 
abrogated increased Foxp3 expression in Batf -/- T cells, without restoring IL-17 
production. This indicates that Batf affects IL-6-mediated downregulation of Foxp3 but 
also regulates additional factors downstream of IL-6 directly required for TH17 
differentiation.  
Consistently, Batf -/- T cells failed to induce the IL-6 target gene IL-21. Further, 
our gene expression profiling experiments demonstrated that Batf was required for the 
expression of numerous IL-6-dependent TH17 associated genes. Specifically, we found 
that genes that were induced in wild type cells in response to either IL-6 alone or IL-6 
plus TGF-β clustered into genes that exhibited Batf-dependent or Batf-independent 
expression. Batf-dependent genes included known TH17 associated genes, such as RORγt 
(Zhou et al., 2007), RORα (Yang et al., 2008), the aryl hydrocarbon receptor (AHR) 
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(Veldhoen et al., 2008; Kimura et al., 2008; Quintana et al., 2008), IL-22 (Liang et al., 
2006) and IL-17. Since we found no effect of Batf on the expression of genes induced in 
response to TGF-β alone, we conclude that Batf specifically regulates the expression of a 
subset of IL-6 induced genes in T cells.  
 
A novel role for AP-1 proteins in the regulation of TH17 differentiation 
The transcriptional regulation of TH17 associated genes is still poorly defined. 
RORγt has been suggested to bind to the proximal Il17 promoter and conserved non-
coding sequences upstream of the Il17 locus (Ichiyama et al., 2008; Zhang et al., 2008b; 
Akimzhanov et al., 2007). Additionally, RORγt can induce Il17 promoter activity in 
reporter assays (Ichiyama et al., 2008; Zhang et al., 2008b) however, since RORγt-/- T 
cells show residual IL-17 production (Ivanov et al., 2006) there are likely other factors 
that regulate Il17 gene transcription. Consistently, RUNX1 has been suggested to 
cooperate with RORγt at the Il17 promoter (Zhang et al., 2008b), NFAT has been 
implicated in regulating Il17 transcription (Liu et al., 2004; Hermann-Kleiter et al., 2008) 
and STAT3 has been shown to bind to the Il17 and Il21 promoters (Wei et al., 2007; 
Chen et al., 2006). 
We have shown that Batf is required for TH17 differentiation and that RORγt 
overexpression does not fully restore IL-17 production in Batf -/- T cells and that the Il17 
promoter is Batf-responsive. Additionally, we found that Batf binds multiple conserved 
non-coding and promoter regions in the Il17a/f locus and the Il21 and Il22 proximal 
promoters in the natural chromatin state during TH17 differentiation. Additionally, using 
EMSA analysis, we found that Batf preferentially dimerizes with JunB in TH17 cells. Our 
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data indicate direct transcriptional regulation of Il17, Il21 and Il22 by Batf and reveal a 
yet unrecognized role for AP-1 transcription factors in the regulation of TH17 associated 
cytokines.  
 
A potential role for Batf as transcriptional activator 
Batf and other AP-1 proteins lacking a TAD are thought to act as AP-1 inhibitors 
by forming transcriptionally inactive heterodimers (Blank, 2008; Williams et al., 2001; 
Echlin et al., 2000; Iacobelli et al., 2000; Dorsey et al., 1995; Thornton et al., 2006). Our 
ChIP and EMSA experiments have shown that Batf binds to multiple regions in the 
Il17a/f locus as well as the Il21 and Il22 promoters indicating direct transcriptional 
regulation of Il17, Il21 and Il22 by Batf. Additionally, the Il17 promoter is Batf 
responsive and Batf is required for the induction of Il17, Il21 and Il22 indicating that Batf 
might directly promote transcription of these genes rather than inhibiting their 
transcription. Consistently, Batf -/- T cells lose the expression of many IL-6 induced genes 
in T cells, whereas Batf deficiency leads to increased expression of only few genes. Since 
Batf preferentially heterodimerizes with JunB during TH17 differentiation, we 
hypothesize that Batf in complex with JunB forms an active transcription factor complex 
in the context of TH17 differentiation.  
Although Batf is also expressed in TH1 and TH2 cells, it appears that Batf is 
specifically necessary for TH17 differentiation, but does not induce this process by itself. 
Rather, our data suggest that Batf cooperates with other TH17-specific factors to regulate 
target genes. In fact, RORγt only partially restores IL-17 production in the absence of 
Batf and our data shows functional synergy between Batf and RORγt. Notably, Batf -/- T 
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cells exhibit a phenotype markedly similar to Irf4-/- T cells, albeit more specific to TH17 
differentiation. Like Batf -/- T cells, Irf4-/- T cells fail to differentiate into TH17 cells, fail 
to downregulate Foxp3 in response to IL-6, and IL-17 production cannot fully be restored 
by RORγt in the absence of either Batf or IRF4. Thus, Batf and IRF4 might cooperate to 
induce TH17 differentiation.  
The hypothesis that Batf acts as a transcriptional repressor is based on the 
underlying assumption that the DNA binding specificity of the ‘inhibitory’ complex is 
identical to the AP-1 complex it replaces. Using bioinformatics approaches, we were able 
to identify a potential Batf-binding motif common to the Batf binding sequences in the 
Il17, Il21 and Il22 promoters. This motif strongly resembles a canonical AP-1 motif at 
positions 1 through 3, but exhibits sequence variation in the remaining nucleotides, thus 
differing from the dyad symmetric AP-1 response element (TGAN(N)TCA). AP-1 
proteins are known to bind to sequences that deviate substantially from consensus AP-1 
elements, particularly in promoters of cytokine genes (Rao et al., 1997). This binding to 
non-consensus sequences often depends on cooperative actions with other transcription 
factors, such as NFAT or IRF (Rao et al., 1997; Panne et al., 2004). Indeed, a study by 
Steve Harrison (Panne et al., 2004) defined the structural basis for binding of the Jun-
ATF2 heterodimer to a non-symmetric non-consensus TGACATAG, which differs from 
the canonical CRE recognition sequence (TGACGTCA) at the three underlined positions.  
The crystal structure of the Jun-ATF2 heterodimer and two IRF3 molecules bound to the 
interferon-β enhanceasome revealed that binding of IRF3 to the DNA induces 
conformational distortion, bending a non-consensus AP-1 sequence into a structure 
compatible for Jun-ATF2 binding. Thus, both binding and transcription mediated by AP-
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1 factors can depend on flanking sequences and interactions with other factors. Therefore, 
Batf and IRF4 might cooperate on the DNA in a manner similar to the cooperation of 
Jun-ATF2 and IRF3 at the interferon-β enhanceasome, enabling the binding of the Batf-
JunB heterodimers to non-consensus binding elements. 
Although we found no significant enrichment of alternative motifs near Batf 
binding sites, identification of alternative motifs enriched near Batf binding sites is 
complicated by the fact that Il17, Il21 and Il22 are differentially regulated by RORγt and 
AHR (Veldhoen et al., 2008), which could both conceivably interact with Batf. Such 
differential regulation would make it more difficult to identify adjacent cooperative cis-
elements near the Batf binding sites in our analysis. Additionally, factors regulating Il17, 
Il21 and Il22 may act at sites located outside the regions examined, may have more 
degenerate target sequences, or may not be common to all cytokine promoters, unlike 
Batf, which appears common to all of these promoters.   
The concept that Batf might function as a transcriptional activator is surprising, 
since Batf lacks an obvious TAD and has been thought to act as AP-1 inhibitor by 
forming transcriptionally inactive heterodimers (Blank, 2008; Williams et al., 2001; 
Echlin et al., 2000; Dorsey et al., 1995; Thornton et al., 2006). However, despite the lack 
of an obvious TAD, Batf might decrease steric hinderance, permitting novel protein-
protein interactions of AP-1 with TH17 specific factors. Alternatively, Batf might change 
the binding affinity of the AP-1 heterodimeric complex, promoting binding of AP-1 to 
novel target sequences. Future studies will have to test the ability of Batf to directly 
induce transcription in reporter assays.  
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In summary, Batf is selectively required for TH17 development. Since Batf is also 
expressed in TH1 and TH2 cells, it likely cooperates with other TH17-specific factors to 
regulate target genes. Future work will need to determine whether the actions of Batf 
involve distinct sequence specificity or unique protein-protein interactions with TH17 
specific factors. 
 
Concluding remarks 
In the studies presented here, we have shown that Batf is required for the 
differentiation of IL-17-producing T helper (TH17) cells (Harrington et al., 2005). TH17 
cells comprise a CD4+ T cell subset that coordinates inflammatory responses in host 
defense but is pathogenic in autoimmunity (Langrish et al., 2005; Ivanov et al., 2006; 
Bettelli et al., 2006; Brustle et al., 2007).  Batf-/- mice have normal TH1 and TH2 
differentiation, but defective TH17 differentiation, and are resistant to experimental 
autoimmune encephalomyelitis.  Batf-/- T cells fail to induce known factors required for 
TH17 differentiation, such as RORγt (Ivanov et al., 2006) and the cytokine IL-21 (Korn et 
al., 2007; Nurieva et al., 2007; Wei et al., 2007; Zhou et al., 2007).  Neither addition of 
IL-21 nor overexpression of RORγt fully restores IL-17 production in Batf-/- T cells.  The 
Il17 promoter is Batf-responsive, and upon TH17 differentiation, Batf binds conserved 
intergenic elements in the Il17a/f locus and to the Il17, Il21 and Il22 (Liang et al., 2006) 
promoters.  These results demonstrate that the AP-1 protein Batf plays a critical role in 
TH17 differentiation and potentially forms an active transcription factor complex, 
although future studies will need to demonstrate direct transcriptional activation of Il17, 
Il21 and Il22 by Batf.  
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APPENDIX 1 
Batf is required for class switch recombination 
 
Introduction 
In addition to cell-mediated immune responses that involve antigen specific CD4+ 
and CD8+ T lymphocytes, the adaptive immune system entails humoral immune 
responses, mediated by B lymphocytes.  B lymphocytes produce and secrete antigen-
specific antibodies that target pathogens for elimination by phagocytic cells or neutralize 
pathogens to prevent cell entry (Murphy et al., 2008). B cell responses include a variety 
of processes involved in the generation of antibody producing plasma cells that secrete 
antigen specific antibodies with high affinity and distinct effector function as well as the 
generation of memory B cells, armed for rapid release of antibodies upon reencountering 
antigen. Additionally, the nature of the humoral immune response is determined by the 
specific B cell subsets involved and the composition of the antigen.  
Antigens can be grouped into two categories; those that elicit T-independent (TI) 
immune responses and those that elicit T dependent (TD) immune responses. TI-1 
antigens, such as bacterial associated lipopolysaccharide (LPS), induce B cell activation 
via germline encoded receptors independent of antigen specificity, leading to B cell 
proliferation, differentiation and antibody secretion. TI-2 antigens are polysaccharides 
present on extracellular bacteria that are characterized by repetitive, identical epitopes. 
These TI antigens induce antigen-specific activation of B cells through their ability to 
strongly crosslink the B cell receptor and generally involve activation of specific B cell 
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subsets, B1 B cells and marginal zone B cells. Nevertheless, TI-2 responses require T cell 
signaling to fully induce B cell responses and proliferation (Alugupalli, 2008).  
In contrast to TI immune responses, B cell responses to most protein antigens 
involve antigen specific T helper cells, thus referred to as TD responses. TD responses 
require coordinate interactions of DC and antigen specific T and B cells in secondary 
lymphoid organs. Antigen specific T cells are activated in the T cell zone of secondary 
lymphoid organs by APCs, such as DCs, that have processed the antigen. These activated 
T cells travel to the T-B cell border where they interact with B cells that have also taken 
up and processed the antigen. This interaction involves antigen presentation to T cells via 
MHCII and costimulatory molecules like CD28 and CD40. This cognate interaction of B 
cells with activated T cells leads to B cell activation, follicular entry and germinal center 
formation. Germinal centers are transient structures that foster an environment in which 
B cells undergo class switch recombination (CSR) and somatic hypermutation allowing 
for the generation of high affinity antibodies (Klein and Dalla-Favera, 2008; Murphy et 
al., 2008). 
The generation of B cells containing high affinity B cell receptors is stringently 
controlled during TD immune responses to prevent the generation of autoreactive B cells 
and entails repeated cognate interactions between B and T cells. Once T cells become 
activated to move to the B cell zone, they acquire the expression of CXCR5, a chemokine 
receptor that facilitates entry into the B cell follicle. These T cells are termed follicular 
helper T (TFH) cells. Whether TFH cells develop as a lineage distinct from TH1, TH2, TH17 
or Treg cells remains controversial, however, recent data suggests dependence of CXCR5 
expression on IL-21 signaling (Tsuji et al., 2009; Fazilleau et al., 2009; Reinhardt et al., 
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2009; Bauquet et al., 2009). Nevertheless, germinal centers also form during TI responses 
in a T cell independent manner (de Vinuesa et al., 2000).  
Class switch recombination is an irreversible somatic mutation mechanism that 
allows B cells to switch their antigen receptors from IgM and IgD to other classes that 
have distinct effector functions. CSR can occur in both T cell dependent and independent 
manner but is ultimately linked to a combination of instructive cytokine and 
costimulatory signals (Klein and Dalla-Favera, 2008; Longerich et al., 2006). Once B 
cells have rearranged their B cell receptor, they can differentiate into either plasma cells 
that are specialized to secrete antibodies, or memory B cells, which become armed to 
secrete antibodies upon reencountering antigen. Activated B cells that do not enter the 
germinal center reaction differentiate into IgM secreting plasma cells or memory cells 
without rearranging their receptor.   
 
Results 
Batf -/- mice have decreased basal immunoglobulin levels.  
In our studies, we determined that B cell development was normal in Batf -/- mice 
(Chapter 3). Since Batf was also expressed at low levels in naïve B cells, we tested 
whether B cell function was affected in the absence of Batf. First, we measured basal 
serum immunoglobulin isotype levels in unimmunized Batf -/- mice of different ages. We 
found that Batf -/- mice had slightly increased IgM serum levels across multiple ages 
examined (Figure 37). Strikingly, we found that Batf -/- mice had severely reduced to non-
detectable serum levels of IgA, IgG1, IgG2a and IgG2b isotypes compared to Batf +/+ 
mice (Figure 37). Thus, Batf -/- B cells show defects in CSR rather than a general defect 
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in antibody secretion suggesting that Batf is required for appropriate antibody responses 
to pathogens.  
 
Batf -/- B cells fail to mount antigen specific IgG3 responses to a T cell independent 
antigen 
The reduced serum Ig levels in Batf -/- mice could result from abnormal generation 
of T helper cells or T follicular helper cells, or alternatively Batf may be required in a cell 
intrinsic manner for B cell CSR and germinal center formation. To address the question 
whether Batf was required in a T or B cell intrinsic manner, and whether Batf -/- mice are 
capable of mounting antigen specific antibody responses we first performed 
immunizations of Batf -/- mice with a TI-2 antigen. We immunized Batf +/+ and Batf -/- 
with 2,4,6,-trinitrophenol (TNP)-conjugated Ficoll (TNP-Ficoll). Batf -/- mice showed 
antigen specific IgM antibodies on days 7 and 14 after immunization. However, Batf -/- 
mice failed to mount and IgG3 response to TNP, whereas Batf +/+ mice mounted a robust 
IgG3 response (Figure 38). These data suggest, that Batf -/- mice can mount an antigen 
specific TI-2 response, however, Batf -/- mice have impaired class switch recombination 
  
Defective class switch recombination in Batf -/- B cells 
 To assess whether class switch recombination was impaired in Batf -/- B cells due 
to a B cell intrinsic requirement for Batf in CSR, we performed in vitro CSR experiments. 
We evaluated class switching in Batf -/- B cells in response LPS in combination with 
various cytokine stimuli. Batf -/- B cells failed to induce CSR under all conditions 
examined (Figure 39 b-d). However, LPS induced secretion of IgM was unaffected in 
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Batf -/- B cells (Figure 39a), indicating that Batf -/- B cells can be activated to secrete 
antibody. Consistently, CD138 expression, a marker for plasma cells was increased in 
Batf -/- B cells, indicating activation of B cells to differentiate into Ig secreting cells. 
Collectively, these data indicate that Batf is required in a cell intrinsic manner for class 
switch recombination.  
 
Discussion  
Although we found that B cell development was normal in Batf -/- mice (Chapter 
3), we wanted to determine, whether Batf deficiency affects B cell function. We found 
that Batf -/- mice had decreased basal serum Ig levels of class switched Ig isotypes 
compared to age matched littermate control mice. Notably, this decrease was 
accompanied by increased serum IgM titers suggesting intact B cell activation and 
plasma cell differentiation in spite of defective class switching. Consistently, Batf -/- mice 
mounted normal antigen specific IgM responses following immunization with the TI 
antigen TNP-Ficoll; however, Batf -/- mice had defective IgG3 responses. Additionally, in 
vitro analysis of Batf -/- B cells demonstrated defective class switching, but normal 
secretion of IgM in response to activation. Notably, Batf -/- B cells preferentially 
developed into plasma cells following LPS stimulation. These data suggest that Batf is 
required for CSR and potentially germinal center B cell formation. 
These observations pose numerous questions and further studies need to define 
the role of Batf in B cell differentiation. Does Batf act as a regulator to induce the 
germinal center B cell transcriptional program or are its functions confined to regulating 
CSR? Notably, Bach2-/- B cells exhibit a phenotype similar to Batf -/- B cells. Bach2-/- B 
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cells show a selective defect in germinal center B cell formation and a defect in CSR with 
normal plasma cell development (Muto et al., 1998). Bach2 seems to be directly involved 
in both, germinal center B cell formation and CSR. Bach2 is a basic leucine zipper 
protein that interacts with small Maf proteins. Like Batf, small Maf proteins lack obvious 
TADs and have been considered to act as inhibitors of transcription (Blank, 2008). While 
these data suggest an important role of AP-1 proteins in B cell differentiation, further 
studies will need to determine whether the actions of Bach2 and Batf are primarily related 
to their ability to modulate AP-1 signaling strength, or due to a yet unrecognized 
specialized ability to induce transcription of target genes.  
The defect in CSR in Batf -/- B cells is very similar to what has been observed in 
Irf4-/- B cells, which are also deficient in CSR. In T cells, we found that both Batf -/- and 
Irf4-/- T cells fail to differentiate into TH17 cells, thus exhibit very similar phenotypes. 
However, Batf specifically affects the TH17 lineage, while Irf4-/- T cells exhibit additional 
defects in TH2 differentiation indicating that the defect observed in Batf -/- T cells is more 
specific than in Irf4-/- T cells. Irf4-/- B cells exhibit defective plasma cell differentiation in 
addition to defective class switch recombination (Sciammas et al., 2006; Klein et al., 
2006), whereas Batf -/- B cells fail to undergo CSR but can develop into plasma cells. 
These observations indicate similar parallel functions of Batf and IRF4 in B cells but 
again the defect in Batf -/- B cells is more specific than the defects in Irf4-/- B cells.  
Further studies will have to determine, whether Batf and IRF4 might cooperate to induce 
transcription in activated B cells, in a manner similar to the cooperation of Jun-ATF2 and 
IRF3 at the interferon-β enhanceasome as discussed in Chapter 8.  
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Concluding remarks 
In the studies presented here, we have shown that Batf -/- mice have decreased 
basal serum immunoglobulin levels and fail to mount antigen specific IgG3 responses 
after immunization with a TI-2 antigen. Notably, antigen specific IgM responses were 
normal in Batf -/- mice. Further, our studies indicated a B cell intrinsic requirement for 
Batf in CSR. Further studies will need to determine the mechanism by which Batf 
regulates CSR.   
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Methods 
In vitro class switch recombination.  
Naïve B cells were isolated from spleens of Batf +/+ and Batf -/- mice using CD43 
microbeads (Miltenyi Biotech Inc.) according to the manufacturer’s recommendation. B 
cells were then cultured at a density of 1e6 cells/ml in 24 well plates for 7 days. To 
induce class switch recombination, B cells were stimulated with LPS from from 
Escherichia coli serotype 0127: B8 (Sigma Aldrich) alone or LPS in combination with 
IL-4 (10ng/ml), IFN-γ (100ng/ml), TGF-β (1ng/ml) (all Peprotech). 7 days later 
supernatants were harvested and analyzed for Ig isotypes using ELISA (SBA clonotyping 
System horseradish peroxidase; Southern Biotech) according to the manufacturer’s 
recommendations. CFSE (Sigma-Aldrich) labeling was performed by incubating cells at 
20 x 106cells/ml in PBS with 1μM CFSE for 8 min at 25 °C. The cells were incubated 
with an equal volume of fetal calf serum (FCS) for 1 min and were washed twice with 
media containing 10% FCS before use.  Cells were analyzed for CD138 expression four 
days after activation by flow cytometry.  
Determination of basal Serum Immunoglobulin Titers.  
For determination of basal serum immunoglobuling titers, serum was collected from sex-
matched mice of different ages (2, 5, 9 and 13 months). Basal serum Immunoglobulin 
levels were determined using ELISA (SBA clonotyping System horseradish peroxidase; 
Southern Biotech) according to the manufacturer’s recommendations.  
Immunizations with TNP-Ficoll. 
Immunizations were preformed using sex and age matched Batf +/+ and Batf -/- mice that 
were between 8 and 10 weeks old. Mice were immunized with 25ug TNP-Ficoll 
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(Biosearch Technologies, Inc.). Mice were bled before immunization (day 0) and on days 
7 and 14 after immunization. TNP-specific IgM and IgG3 antibody responses were 
measured by ELISA against plate-bound TNP-conjugated bovine serum albumin using 
serial dilutions of serum and isotype specific HRP-conjugated secondary antibodies 
(Southern Biotech). The TNP specific titers were defined as the greatest serial dilution at 
which the average optical density at 405nm exceeded 1.5 fold of the background optical 
density.  
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Figure 37. Batf -/- mice have decreased basal serum Immunoglobulin concentrations.  
Sera from Batf +/+ and Batf -/- mice at the indicated ages were analyzed for serum Ig 
concentrations using ELISA. Data are presented as mean + s.e.m. of 3-5 mice analyzed per 
group.  
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Figure 38. Batf -/- mice fail to mount antigen specific IgG3 responses to a T cell independent 
antigen.  
Batf +/+ and Batf -/- mice were immunized with TNP-Ficoll. Mice were bled before 
immunization (day 0) and on days 7 and 14 after immunization. TNP-specific IgM and IgG3 
antibody responses were measured by ELISA against plate-bound TNP-conjugated bovine 
serum albumin using serial dilutions of serum. The TNP specific titers were defined as the 
greatest serial dilution at which the average optical density at 405nm exceeded 1.5 fold of 
the background optical density. Horizontal bars indicate mean values.  
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Figure 39. Defective class switch recombination in Batf -/- B cells.   
a - d, Naïve B cells were isolated from Batf +/+ and Batf -/- mice by negative selection using 
CD43 magnetic beads. B cells were then activated with either LPS alone (a), LPS + IL-4 (b), 
LPS + IFN-γ (c), or LPS + TGF-β (d). On day 7 supernatants were collected and analyzed 
for the indicated Ig isotypes by ELISA. e, B cells from Batf +/+ and Batf -/-  were CFSE labeled 
and treated with LPS + IL-4. On day 4 after activation B cells were analyzed for CFSE 
dilution and CD138 expression by Flow cytometry. Number indicated the percentage of live 
cells in each gate.  
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